1
|
Sun T, Wang J, Zheng M, Cai C, Yu J, Fu L, Duan L. Assessment of the Relationship Between Genetic Determinants of Obesity, Unhealthy Eating Habits and Chronic Obstructive Pulmonary Disease: A Mendelian Randomisation Study. COPD 2024; 21:2309236. [PMID: 38348880 DOI: 10.1080/15412555.2024.2309236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2023] [Accepted: 01/18/2024] [Indexed: 02/15/2024]
Abstract
Background: Clinical studies have shown that the onset and exacerbation of chronic obstructive pulmonary disease (COPD) are related to obesity and dietary behaviours, but the genetic relationship between them is not clear.Aims: To investigate the relationship between the genetic determinants of obesity, dietary habits (alcohol consumption, intake of sweets, salt intake) and COPD.Methods: Exposure and outcome datasets were obtained from the IEU Open GWAS project. The exposure dataset includes dietary habits (Salt added to food, Sweets intake, Alcohol consumption), obesity level (represented by body mass index (BMI) and body fat percentage (BFP) data sets.). The outcome dataset includes COPD and acute COPD admissions. The collected data were imported into the RStudio software and conducted Mendelian randomisation analysis. Additionally, heterogeneity and horizontal pleiotropy tests were conducted on the data to ensure the veracity of the results.Results: The results showed that BMI was positively correlated with the risk of acute COPD admission (OR = 1.74, 95% CI 1.39-2.18) and COPD (OR = 1.81, 95%CI 1.41-2.33). In addition, BFP was also a risk factor for COPD (OR = 1.98, 95% CI 1.42-2.77) and acute exacerbation of COPD admission (OR = 1.99, 95%CI 1.43-2.77). The increase of salt, sugar and alcohol consumption will not increase the risk of COPD and the risk of hospitalisation due to COPD.Conclusion: Therefore, we should strengthen the guidance of diet and living habits of obese patients. For patients with heavier weight and higher body fat rate, they should be instructed to lose weight and fat to prevent the occurrence of COPD. For obese patients with COPD, more attention should be paid to prevent the occurrence of acute exacerbation of COPD in advance.
Collapse
Affiliation(s)
- Tongyao Sun
- Shandong University of Traditional Chinese Medicine First Clinical Medical College, Shandong, China
| | - Jun Wang
- Respiratory and Critical Care Medicine Department, Shandong University of Traditional Chinese Medicine Second Affiliated Hospital, Shandong, China
| | - Min Zheng
- Shandong University of Traditional Chinese Medicine First Clinical Medical College, Shandong, China
| | - Chengsen Cai
- Respiratory and Critical Care Medicine Department, Shandong University of Traditional Chinese Medicine Second Affiliated Hospital, Shandong, China
| | - Jianjian Yu
- Respiratory and Critical Care Medicine Department, Shandong University of Traditional Chinese Medicine Second Affiliated Hospital, Shandong, China
| | - Lina Fu
- Respiratory and Critical Care Medicine Department, Shandong University of Traditional Chinese Medicine Second Affiliated Hospital, Shandong, China
| | - Lei Duan
- Medical Affairs Department, Shandong University of Traditional Chinese Medicine Second Affiliated Hospital, Shandong, China
| |
Collapse
|
2
|
He P, Wang D, Zheng R, Wang H, Fu L, Tang G, Shi Z, Wu Y, Yang G. An antibacterial biologic patch based on bacterial cellulose for repair of infected hernias. Carbohydr Polym 2024; 333:121942. [PMID: 38494213 DOI: 10.1016/j.carbpol.2024.121942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2023] [Revised: 02/08/2024] [Accepted: 02/09/2024] [Indexed: 03/19/2024]
Abstract
Infection-associated complications and repair failures and antibiotic resistance have emerged as a formidable challenge in hernia repair surgery. Consequently, the development of antibiotic-free antibacterial patches for hernia repair has become an exigent clinical necessity. Herein, a GBC/Gel/LL37 biological patch (biopatch) with exceptional antibacterial properties is fabricated by grafting 2-Methacryloyloxyethyl trimethylammonium chloride (METAC), a unique quaternary ammonium salt with vinyl, onto bacterial cellulose (GBC), followed by compounding with gelatin (Gel) and LL37. The GBC/Gel/LL37 biopatch exhibits stable swelling capacity, remarkable mechanical properties, flexibility, and favorable biocompatibility. The synergistic effect of METAC and LL37 confers upon the GBC/Gel/LL37 biopatch excellent antibacterial efficacy against Staphylococcus aureus and Escherichia coli, effectively eliminating invading bacteria without the aid of exogenous antibiotics in vivo while significantly reducing local acute inflammation caused by infection. Furthermore, the practical efficacy of the GBC/Gel/LL37 biopatch is evaluated in an infected ventral hernia model, revealing that the GBC/Gel/LL37 biopatch can prevent the formation of visceral adhesions, facilitate the repair of infected ventral hernia, and effectively mitigate chronic inflammation. The prepared antibacterial GBC/Gel/LL37 biopatch is very effective in dealing with the risk of infection in hernia repair surgery and offers potential clinical opportunities for other soft injuries, exhibiting considerable clinical application prospects.
Collapse
Affiliation(s)
- Pengyu He
- Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China
| | - Dawei Wang
- Department of Plastic and Cosmetic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan 430030, Hubei, China
| | - Ruizhu Zheng
- Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China
| | - Hao Wang
- Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China
| | - Lina Fu
- College of Medicine, Huanghuai University, Zhumadian, Henan 463000, China; Zhumadian Central Hospital, Zhumadian, Henan 463000, China
| | - Guoliang Tang
- Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China
| | - Zhijun Shi
- Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China.
| | - Yiping Wu
- Department of Plastic and Cosmetic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan 430030, Hubei, China.
| | - Guang Yang
- Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China.
| |
Collapse
|
3
|
Wang C, Wang Z, Fu L, Du J, Ji F, Qiu X. CircNRCAM up-regulates NRCAM to promote papillary thyroid carcinoma progression. J Endocrinol Invest 2024; 47:1215-1226. [PMID: 38485895 DOI: 10.1007/s40618-023-02241-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/18/2023] [Accepted: 11/04/2023] [Indexed: 04/23/2024]
Abstract
PURPOSE Papillary Thyroid Carcinoma (PTC) is the most prevalent subtype of Thyroid Carcinoma (THCA), a type of malignancy in the endocrine system. According to prior studies, Neural Cell Adhesion Molecule (NRCAM) has been found to be up-regulated in PTC and stimulates the proliferation and migration of PTC cells. However, the specific mechanism of NRCAM in PTC cells is not yet fully understood. Consequently, this study aimed to investigate the underlying mechanism of NRCAM in PTC cells, the findings of which could provide new insights for the development of potential treatment targets for PTC. METHODS AND RESULTS Bioinformatics tools were utilized and a series of experiments were conducted, including Western blot, colony formation, and dual-luciferase reporter assays. The data collected indicated that NRCAM was overexpressed in THCA tissues and PTC cells. Circular RNA NRCAM (circNRCAM) was found to be highly expressed in PTC cells and to positively regulate NRCAM expression. Through loss-of-function assays, both circNRCAM and NRCAM were shown to promote the proliferation, invasion, and migration of PTC cells. Mechanistically, this study confirmed that precursor microRNA-506 (pre-miR-506) could bind with m6A demethylase AlkB Homolog 5 (ALKBH5), leading to its m6A demethylation. It was also discovered that circNRCAM could competitively bind to ALKBH5, which restrained miR-506-3p expression and promoted NRCAM expression. CONCLUSION In summary, circNRCAM could up-regulate NRCAM by down-regulating miR-506-3p, thereby enhancing the biological behaviors of PTC cells.
Collapse
Affiliation(s)
- C Wang
- Department of Thyroid Surgery, The First Affiliated Hospital of Zhengzhou University, No. 1 East Jianshe Road, Zhengzhou, 450052, Henan, China
| | - Z Wang
- Department of Thyroid Surgery, The First Affiliated Hospital of Zhengzhou University, No. 1 East Jianshe Road, Zhengzhou, 450052, Henan, China
| | - L Fu
- Department of Thyroid Surgery, The First Affiliated Hospital of Zhengzhou University, No. 1 East Jianshe Road, Zhengzhou, 450052, Henan, China
| | - J Du
- Department of Thyroid Surgery, The First Affiliated Hospital of Zhengzhou University, No. 1 East Jianshe Road, Zhengzhou, 450052, Henan, China
| | - F Ji
- Department of Thyroid Surgery, The First Affiliated Hospital of Zhengzhou University, No. 1 East Jianshe Road, Zhengzhou, 450052, Henan, China
| | - X Qiu
- Department of Thyroid Surgery, The First Affiliated Hospital of Zhengzhou University, No. 1 East Jianshe Road, Zhengzhou, 450052, Henan, China.
| |
Collapse
|
4
|
Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kaźmierczak M, Lamanna N, O'Brien SM, Tam CS, Qiu L, Zhou K, Simkovic M, Mayer J, Gillespie-Twardy A, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, Osterborg A, Yimer HA, Salmi T, Wang MDY, Fu L, Li J, Wu K, Cohen A, Shadman M. Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment. Future Oncol 2024; 20:717-726. [PMID: 38088119 DOI: 10.2217/fon-2023-0849] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/26/2024] Open
Abstract
WHAT IS THIS SUMMARY ABOUT? This is a plain language summary of a research study called ALPINE. The study involved people who had been diagnosed with, and previously treated at least once for, relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Lymphocytes help to find and fight off viruses and infections in the body, but when someone has CLL or SLL, the body creates abnormal lymphocytes, leaving the patient with a weakened immune system and susceptible to illness. In CLL, these lymphocytes are in the bone marrow and bloodstream, whereas for SLL, they are mostly found in the lymph nodes, such as those in the neck. HOW WAS THE RESEARCH DONE? The ALPINE study was designed to directly compare the cancer-fighting effects and side effects of zanubrutinib and ibrutinib as treatment for patients with relapsed or refractory CLL/SLL. WHAT WERE THE RESULTS? After 30 months, zanubrutinib was more effective than ibrutinib at reducing and keeping the cancer from coming back. Clinical Trial Registration: NCT03734016 (ClinicalTrials.gov).
Collapse
Affiliation(s)
- Jennifer R Brown
- The Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
| | - Barbara Eichhorst
- The Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany
| | - Peter Hillmen
- St. James's University Hospital, Leeds, United Kingdom
| | - Wojciech Jurczak
- Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland
| | - Maciej Kaźmierczak
- The Department of Hematology & Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland
| | - Nicole Lamanna
- Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA
| | - Susan M O'Brien
- Chao Family Comprehensive Cancer Center, University of California, Irvine, California, USA
| | | | - Lugui Qiu
- The State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
| | - Keshu Zhou
- The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
| | - Martin Simkovic
- The Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove, Czech Republic, & The First Faculty of Medicine, Charles University, Prague, & the Department of Internal Medicine, Prague, Czech Republic
| | - Jiri Mayer
- Hematology & Oncology, Masaryk University & University Hospital, Brno, Czech Republic
| | | | - Alessandra Ferrajoli
- The Leukemia Department, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
| | - Peter S Ganly
- The Department of Haematology, Christchurch Hospital, Christchurch, New Zealand
| | - Robert Weinkove
- Te Rerenga Ora Blood & Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast & Hutt Valley, & the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand
| | - Sebastian Grosicki
- The Department of Hematology & Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice, Poland
| | - Andrzej Mital
- The Department of Hematology & Transplantology, Medical University of Gdańsk, Gdańsk, Poland
| | | | - Anders Osterborg
- The Department of Oncology-Pathology, Karolinska Institutet, Stockholm & the Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
| | - Habte A Yimer
- Texas Oncology-Tyler, US Oncology Network, Tyler, Texas, USA
| | - Tommi Salmi
- BeiGene International GmbH, Basel, Switzerland
| | | | | | | | | | | | - Mazyar Shadman
- The Fred Hutchinson Cancer Center & the Department of Medicine, University of Washington, Seattle, USA
| |
Collapse
|
5
|
Fu L, Mao YS. [Progress in correlation between lymph node metastasis and prognosis of esophageal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi 2024; 27:84-91. [PMID: 38262906 DOI: 10.3760/cma.j.cn441530-20230407-00105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 01/25/2024]
Abstract
The status of lymph node metastasis is an important parameter affecting the survival of patients with esophageal carcinoma, which is primarily determined by histological type and the depth of invasion. However, affected by pathological features, heterogeneity and individual differences of tumors, the present staging system of lymph node in esophageal carcinoma has not been unified, the rule of lymph node metastasis remains unclear, and the extent of lymphadenectomy is still controversial. Current lymph node staging system for esophageal carcinoma may be not effective enough, which may lead to inaccurate assessment of the stage and affect the clinicians' choice of treatment modalities, or even affect the conclusions of clinical trials. Therefore, it is essential to optimize the current lymph node staging system for esophageal carcinoma to guide the surgery-based multidisciplinary treatment, and effectively to evaluate the therapeutic effects and predict patients' prognosis.
Collapse
Affiliation(s)
- L Fu
- Department of Thoracic Surgery, National Cancer Center, National Clinical Research Center for Cancer & Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Y S Mao
- Department of Thoracic Surgery, National Cancer Center, National Clinical Research Center for Cancer & Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| |
Collapse
|
6
|
Wu S, Gao Y, Guo S, Fu L, Ying Y, Wu W, Hou L, Liang Y, Luo X. Characterization of newly diagnosed type 1 diabetes in children and adolescents from 2017 to 2022 in China: a single-center analysis. BMC Pediatr 2024; 24:13. [PMID: 38178064 PMCID: PMC10765937 DOI: 10.1186/s12887-023-04498-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/20/2023] [Accepted: 12/20/2023] [Indexed: 01/06/2024] Open
Abstract
OBJECTIVE This study investigated the characteristics of newly diagnosed type 1 diabetes mellitus (T1DM) related to autoimmunity and the frequency of diabetic ketoacidosis (DKA) in children and adolescents from 2017-2022 in China. RESEARCH DESIGN AND METHODS Single-center regional data from the Department of Pediatric Endocrinology, Tongji Hospital, were used to compare 88 children and adolescents newly diagnosed with T1DM from 2020 to 2022 (i.e. during the COVID-19 pandemic in China) and 76 children and adolescents diagnosed with T1DM from 2017 to 2019. Auto-antibodies, including glutamic acid decarboxylase-65 and insulin auto-antibodies, were detected by enzyme-linked immunoassays. DKA was defined as a pH < 7.3 and/or a bicarbonate level < 15 mmol/L. RESULTS The median age of the 164 children and adolescents newly diagnosed with T1DM from 2017 to 2022 was 7.0 years (interquartile range [IQR]: 3.8-10.0 years; 51.83% male). The mean annual incidence of T1DM was 2.98 per 1,000,000 child years. The estimated frequency of auto-antibody positivity was 51.22% (n = 84), and there was no difference between the 2020-2022 group and 2017-2019 group (55.68% [n = 49] vs. 46.5% [n = 35]; p = 0.219). The frequency of DKA among the entire cohort was 57.93% (n = 95), and peaked in 2020 at 78.9% (15/19 patients). The frequency of DKA was not significantly higher in the 2020-2022 group compared with the 2017-2019 group (60.23% [n = 53] vs. 55.26% [n = 42]; p = 0.521). We found no significant difference in the frequency of DKA between patients who were negative vs. positive for auto-antibodies in the 2020-2022 group (64.10% [n = 25] vs. 57.14% [n = 28], p > 0.05). The C-peptide level and HbA1c (%) were positively correlated with onset age (R1 = 0.389, p < 0.01; R2 = 0.371, p < 0.01), and the estimated mean C-peptide level was 0.26 ng/ml (IQR: 0.2-0.4 ng/ml) in patients with DKA and 0.370 ng/ml (IQR: 0.2-0.6 ng/ml) in patients without DKA (p = 0.044). CONCLUSIONS This study showed the annual incidence of T1DM was 2.98 per 1,000,000 child years, gradually increased over the study period, and there was no significant increase in T1DM with auto-antibody positivity in children and adolescents newly diagnosed from 2020-2022 in China compared with the previous 3 years. Furthermore, the frequency of DKA was peaked in 2020, and were not significantly different between patients who were negative vs. positive for auto-antibodies.
Collapse
Affiliation(s)
- Shimin Wu
- Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Yuan Gao
- Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Shusen Guo
- Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Lina Fu
- Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Yanqin Ying
- Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Wei Wu
- Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Ling Hou
- Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Yan Liang
- Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Xiaoping Luo
- Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
| |
Collapse
|
7
|
Yang XF, Zhao XT, Xie HX, Guan M, Fu L, Jiang Y, Hou XT, Hei FL. [Myocardial protection of del Nido cardioplegia in adult cardiac and major vascular surgery with long aortic cross-clamp time]. Zhonghua Yi Xue Za Zhi 2023; 103:3917-3923. [PMID: 38129168 DOI: 10.3760/cma.j.cn112137-20231008-00669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 12/23/2023]
Abstract
Objective: To explore the safety and myocardial protection efficacy of del Nido cardioplegia in adult cardiac and major vascular surgery with long aortic cross-clamp (ACC) time. Methods: A total of 2 536 patients who underwent adult cardiac and major vascular surgery with ACC time>90 min at Beijing Anzhen Hospital from March 2018 to March 2023 were collected. The patients were divided into two groups according to the type of cardioplegia solution: the del Nido cardioplegia solution group (DC group) and the cold blood cardioplegia solution group (BC group). Preoperative baseline data of the patients (age, gender, comorbidities, ejection fraction, etc) were adjusted using propensity score matching (PSM). Cardiopulmonary bypass (CPB) time, ACC time, total amount of cardioplegia solution, in-hospital mortality rate, length of intensive care unit (ICU) stay, mechanical ventilation time, postoperative complications, left ventricular ejection fraction, and troponin levels were compared between the two groups. Results: After PSM, a total of 306 patients were included, including 223 males and 83 females, with a mean age of (52.0±12.3) years. There were 153 cases in the DC group and 153 cases in the BC group. Compared with the DC group, the cross-clamp time was longer [109(100, 150) min vs 102(91, 133) min, P<0.001], the rate of return to spontaneous rhythm was lower [51.6% (79/153) vs 86.9%(133/153), P<0.001], and intraoperative peak glucose was higher [12.6 (6.5, 15.9) mmol/L vs 10.1 (8.5, 12.4) mmol/L, P=0.005] in the BC group. In addition, perioperative mortality [4.6% (7/153) vs 3.3% (5/153), P=0.132], stroke[3.9% (6/153) vs 3.3% (5/153), P=0.759], renal insufficiency [3.3% (5/153) vs 6.5% (10/153), P=0.186], atrial fibrillation [4.6% (7/153) vs 2.6% (4/153), P=0.652] and low cardiac output syndrome [3.9% (6/153) vs 4.6% (7/153), P=0.716] did not differ between the two groups. Compared with BC group, DC group had lower level of high sensitivity troponin (hsTnI) [1.2 (0.8, 1.8) μg/L vs 1.3 (0.9, 2.3) μg/L, P=0.030] and creatine kinase isoenzyme (CK-MB) [31.0 (20.0, 48.9) μg/L vs 37.0 (24.0, 58.9) μg/L, P=0.011] at 24 h postoperatively, and shorter length of ICU stay [35.6 (19.8, 60.5) h vs 42.6 (21.9, 83.6) h, P=0.015] and mechanical ventilation time [20.5 (15.5, 41.0) h vs 31.5 (17.1, 56.0) h, P=0.012]. Subgroup analysis showed that in the 120-180 minute subgroup, patients in the DC group had a shorter cross-clamp time [132 (124, 135) min vs 136 (124, 138) min, P<0.001], while levels of hsTnI [1.6 (1.1, 2.0) μg/L vs 1.4 (1.0, 2.6) μg/L, P=0.030] and CK-MB [38.8 (23.5, 55.5) μg/L vs 37.0 (24.5, 62.3) μg/L, P=0.011] were higher than those in the BC group. Conclusions: In adult cardiac and major vascular surgery with ACC times>90 min, comparable myocardial protection is observed with the use of DC compared with BC. Additional advantages in glycemic control, return to spontaneous rhythm, and improved surgical procedures make DN an attractive alternative for myocardial protection in adult cardiac surgery.
Collapse
Affiliation(s)
- X F Yang
- Center for Cardiac Intensive Care, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China
| | - X T Zhao
- Department of Extracorporeal Circulation and Mechanical Circulation Assistants, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China
| | - H X Xie
- Department of Extracorporeal Circulation and Mechanical Circulation Assistants, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China
| | - M Guan
- Department of Extracorporeal Circulation and Mechanical Circulation Assistants, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China
| | - L Fu
- Department of Extracorporeal Circulation and Mechanical Circulation Assistants, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China
| | - Y Jiang
- Department of Extracorporeal Circulation and Mechanical Circulation Assistants, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China
| | - X T Hou
- Center for Cardiac Intensive Care, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China
| | - F L Hei
- Department of Extracorporeal Circulation and Mechanical Circulation Assistants, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China
| |
Collapse
|
8
|
Mbituyimana B, Adhikari M, Qi F, Shi Z, Fu L, Yang G. Microneedle-based cell delivery and cell sampling for biomedical applications. J Control Release 2023; 362:692-714. [PMID: 37689252 DOI: 10.1016/j.jconrel.2023.09.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2023] [Revised: 08/16/2023] [Accepted: 09/04/2023] [Indexed: 09/11/2023]
Abstract
Cell-based therapeutics are novel therapeutic strategies that can potentially treat many presently incurable diseases through novel mechanisms of action. Cell therapies may benefit from the ease, safety, and efficacy of administering therapeutic cells. Despite considerable recent technological and biological advances, several barriers remain to the clinical translation and commercialization of cell-based therapies, including low patient compliance, personal handling inconvenience, poor biosafety, and limited biocompatibility. Microneedles (MNs) are emerging as a promising biomedical device option for improved cell delivery with little invasion, pain-free administration, and simplicity of disposal. MNs have shown considerable promise in treating a wide range of diseases and present the potential to improve cell-based therapies. In this review, we first summarized the latest advances in the various types of MNs developed for cell delivery and cell sampling. Emphasis was given to the design and fabrication of various types of MNs based on their structures and materials. Then we focus on the recent biomedical applications status of MNs-mediated cell delivery and sampling, including tissue repair (wound healing, heart repair, and endothelial repair), cancer treatment, diabetes therapy, cell sampling, and other applications. Finally, the current status of clinical application, potential perspectives, and the challenges for clinical translation are also highlighted.
Collapse
Affiliation(s)
- Bricard Mbituyimana
- Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, China
| | - Manjila Adhikari
- Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, China
| | - Fuyu Qi
- Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, China
| | - Zhijun Shi
- Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, China.
| | - Lina Fu
- College of Medicine, Huanghuai University, Zhumadian, Henan 463000, China; Zhumadian Central Hospital, Zhumadian, Henan 463000, China.
| | - Guang Yang
- Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, China.
| |
Collapse
|
9
|
Wang L, Zou B, Huang W, Shao Q, Meng X, Tang X, Zhang P, Hu X, Zhang Y, Guo J, Fu L, Zhao W, Zhao C, Yuan J, Yu J, Chen D. Safety and Efficacy Analysis of Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Treated with SHR-1316 Plus Chemotherapy and Sequential Chest Radiotherapy as First-Line Therapy from a Phase II Trial. Int J Radiat Oncol Biol Phys 2023; 117:S58-S59. [PMID: 37784531 DOI: 10.1016/j.ijrobp.2023.06.354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) CAPSTONE-1, a phase 3 trial, showed that SHR-1316 (PD-L1 antibody) combined with standard first-line chemotherapy could prolong overall survival (OS) in patients (pts) with ES-SCLC. The CREST trial reported consolidative thoracic radiotherapy (TRT) of 30 Gy in 10 fractions provided a 10% 2-year OS benefit and more intensive TRT should be investigated in ES-SCLC. In the era of immunotherapy, the role of TRT also needs further exploration. Therefore, we designed this clinical trial to investigate the efficacy and safety of SHR-1316 plus first-line chemotherapy followed by TRT combined with SHR-1316. MATERIALS/METHODS Key inclusion criteria were pts aged 18-75 years, with previously untreated histologically or cytologically confirmed ES-SCLC, and an ECOG performance status of 0-1. Eligible pts would receive 4∼6 cycles of SHR-1316 (20mg/kg, D1, q3w) combined with EP/EC (etoposide, 100mg/m2, D1-5, q3w and cisplatin, 75mg/m², D1-3, q3w or carboplatin, AUC = 5, D1, q3w), followed by SHR-1316 combined with TRT (≥3 Gy*10 f or ≥2 Gy*25 f, involved-field irradiation), and then the maintenance therapy with SHR-1316 until disease progression or intolerable adverse events (AEs). The main endpoints included ORR, PFS and safety. RESULTS From October 2020 to January 2023, 33 pts received SHR-1316 and sequential consolidative TRT. Among them, 19 pts received high-dose TRT (>3 Gy*10 f or ≥2 Gy*25 f) and 14 pts received low-dose TRT (≤3 Gy*10 f or<2 Gy*25 f). The median age was 62 (range: 38-73). Most pts were male (28, 84.8%), former smokers (22, 66.7%) with an ECOG performance status 1 (32, 97%). Ten (30.3%) pts were diagnosed with brain metastasis and 10 (30.3%) pts had liver metastasis at baseline. At the data cutoff date, 9 pts remained on treatment, the average number of treatment cycles was 9.2. 33 pts had at least one 1 post-treatment tumor assessment. The confirmed ORR and DCR were 90.9% (30/33) and 100% (33/33) in all pts, were 89.5% (17/19) and 100% (19/19) in high-dose TRT group, and were 92.9% (13/14) and 100% (14/14) in low-dose TRT group. The median PFS was 10.2(CI: 5.8∼14.7) months in all pts, was 7 (CI: 3.8∼10.2) months in high-dose TRT group and 10.4 (CI: 8.4∼12.3) months in low-dose TRT group. AEs occurred in 27 (81.8%) pts and grade 3 or 4 AEs occurred in 20 (60.6%) pts. The most common grade 3 or 4 AEs included neutropenia (15, 45.5%), leukopenia (8, 24.2%), lymphocytopenia (5, 15.2%), pneumonia (3, 9.1%), anemia (3, 9.1%) and thrombocytopenia (2, 6.1%). CONCLUSION SHR-1316 plus chemotherapy and sequential TRT as first-line therapy for ES-SCLC showed promising efficacy and acceptable safety. There is no significant difference between high-dose and low-dose TRT groups in terms of safety and efficacy according to current data.
Collapse
Affiliation(s)
- L Wang
- Shandong Cancer Hospital, Shandong University, Jinan, China
| | - B Zou
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - W Huang
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - Q Shao
- Shandong Cancer Hospital and Institute, Jinan, China
| | - X Meng
- Shandong Cancer Hospital, Shandong University, Jinan, China
| | - X Tang
- Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan 250117, Shandong Province, China
| | - P Zhang
- Shandong Cancer Hospital, Shandong University, Jinan, China
| | - X Hu
- Shandong Cancer Hospital, Shandong University, Jinan, China
| | - Y Zhang
- Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan 250117, Shandong Province, China
| | - J Guo
- Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan 250117, Shandong Province, China
| | - L Fu
- Shandong Cancer Hospital, Shandong University, Jinan, China
| | - W Zhao
- Shandong Cancer Hospital, Shandong University, Jinan, China
| | - C Zhao
- Jiangsu Hengrui Pharmaceuticals Co. Ltd, Shanghai, China
| | - J Yuan
- Jiangsu Hengrui Pharmaceuticals Co. Ltd, Shanghai, China
| | - J Yu
- Shandong Cancer Hospital, Shandong University, Jinan, Shandong, China
| | - D Chen
- Shandong Cancer Hospital, Shandong University, Jinan, China
| |
Collapse
|
10
|
Fu L, Shen L, Bian JJ, Li L, Su YX, Zuo JM, Meng ML, Lu Y, Ge SY, Wang DC. [Optic neuritis induced by Dasatinib in patients with Ph(+) acute lymphoblastic leukemia: a case report]. Zhonghua Xue Ye Xue Za Zhi 2023; 44:608. [PMID: 37749048 PMCID: PMC10509613 DOI: 10.3760/cma.j.issn.0253-2727.2023.07.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Received: 12/11/2022] [Indexed: 09/27/2023]
Affiliation(s)
- L Fu
- Department of Hematology, the Second Affiliated Hospital of Bengbu Medical College, Bengbu 233020, China
| | - L Shen
- Department of Hematology, the Second Affiliated Hospital of Bengbu Medical College, Bengbu 233020, China
| | - J J Bian
- Department of Hematology, the Second Affiliated Hospital of Bengbu Medical College, Bengbu 233020, China
| | - L Li
- Department of Hematology, the Second Affiliated Hospital of Bengbu Medical College, Bengbu 233020, China
| | - Y X Su
- Department of Hematology, the Second Affiliated Hospital of Bengbu Medical College, Bengbu 233020, China
| | - J M Zuo
- Department of Hematology, the Second Affiliated Hospital of Bengbu Medical College, Bengbu 233020, China
| | - M L Meng
- Department of Hematology, the Second Affiliated Hospital of Bengbu Medical College, Bengbu 233020, China
| | - Y Lu
- Department of Hematology, the Second Affiliated Hospital of Bengbu Medical College, Bengbu 233020, China
| | - S Y Ge
- Department of Hematology, the Second Affiliated Hospital of Bengbu Medical College, Bengbu 233020, China
| | - D C Wang
- Department of Hematology, the Second Affiliated Hospital of Bengbu Medical College, Bengbu 233020, China
| |
Collapse
|
11
|
Xu YX, Zhang MR, Fu L. [Current application and limitations of augmented reality in the stomatology]. Zhonghua Kou Qiang Yi Xue Za Zhi 2023; 58:594-599. [PMID: 37272005 DOI: 10.3760/cma.j.cn112144-20230106-00004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Computer-assisted technology are gradually integrated into dental education and clinical treatment. As a cutting-edge technology in computer-aided medicine, augmented reality can not only be used as an aid to dental education by presenting three-dimensional scenes for teaching demonstration and experimental skills training, but also can superimpose virtual image information of patients onto real lesion areas for real-time feedback and intraoperative navigation. This review explores the current applications and limitations of augmented reality in dentistry to provide a reference for future research.
Collapse
Affiliation(s)
- Y X Xu
- Department of Oral Implantology, Hospital of Stomatology, Jilin University, Changchun 130021, China
| | - M R Zhang
- Department of Oral Implantology, Hospital of Stomatology, Jilin University, Changchun 130021, China
| | - L Fu
- Department of Oral Implantology, Hospital of Stomatology, Jilin University, Changchun 130021, China
| |
Collapse
|
12
|
Fu L, Li L, Shen L, Bian JJ, Su YX, Zuo JM, Meng ML, Lu Y, Ge SY. [Multiple primary myeloid sarcoma in a child with t(16;21)(p11;q22)-TLS-ERG fusion gene]. Zhonghua Er Ke Za Zhi 2023; 61:467-469. [PMID: 37096269 DOI: 10.3760/cma.j.cn112140-20220922-00830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 04/26/2023]
Affiliation(s)
- L Fu
- Department of Hematology, the Second Affiliated Hospital of Bengbu Medical College,Bengbu 233020,China
| | - L Li
- Department of Hematology, the Second Affiliated Hospital of Bengbu Medical College,Bengbu 233020,China
| | - L Shen
- Department of Hematology, the Second Affiliated Hospital of Bengbu Medical College,Bengbu 233020,China
| | - J J Bian
- Department of Hematology, the Second Affiliated Hospital of Bengbu Medical College,Bengbu 233020,China
| | - Y X Su
- Department of Hematology, the Second Affiliated Hospital of Bengbu Medical College,Bengbu 233020,China
| | - J M Zuo
- Department of Hematology, the Second Affiliated Hospital of Bengbu Medical College,Bengbu 233020,China
| | - M L Meng
- Department of Hematology, the Second Affiliated Hospital of Bengbu Medical College,Bengbu 233020,China
| | - Y Lu
- Department of Hematology, the Second Affiliated Hospital of Bengbu Medical College,Bengbu 233020,China
| | - S Y Ge
- Department of Hematology, the Second Affiliated Hospital of Bengbu Medical College,Bengbu 233020,China
| |
Collapse
|
13
|
Qi XT, Zheng LY, Fu L, Zhang WY, Wang N, Chen XY, Lu Y. [Protective effect of anti-idiopathic pulmonary fibrosis drug Pirfenidone and Sufenidone (SC1011) on pulmonary injury induced by tuberculosis in a mouse tuberculosis model]. Zhonghua Jie He He Hu Xi Za Zhi 2023; 46:388-395. [PMID: 36990703 DOI: 10.3760/cma.j.cn112147-20220914-00758] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 03/31/2023]
Abstract
Objective: To evaluate the protective effect of anti-idiopathic pulmonary fibrosis (IPF) marketed drug Pirfenidone and its clinical drug Sufenidone (SC1011) against lung injury in a mouse tuberculosis model. Methods: C57BL/6 mouse model of tuberculosis was established. A total of 75 C57BL/6 mice were infected with 1×107 CFU/ml H37Rv suspension by aerosol and randomly divided into untreated (n=9) group, isoniazid+rifampicin+pyrazinamide (HRZ) group (n=22), PFD+HRZ group (n=22), and SC1011+HRZ group (n=22). C57BL/6 mice were infected with H37Rv by aerosol for 6 weeks and then treated. Seven mice in each treatment group were weighed, sacrificed, dissected and observed for lung and spleen lesions at 4 and 8 weeks of treatment. HE staining and Masson staining were used to assess degree of lung injury and fibrosis, respectively. ELISA was used to assess the IFN-γ/TNF-α content in the serum of mice in each treatment group after 4 weeks of treatment. Hydroxyproline (HYP) content in lung tissue was measured by alkaline hydrolysis; meanwhile, CFU counts were used to assess the bacterial load in the lung and spleen of mice in each treatment group and the recurrence of spleen and lung tissue after 12 weeks of drug withdrawal. Results: At 8 weeks, the HYP content in the lung tissue was (630±58), (635±17), and (840±70) μg/mg in the PFD+HRZ, SC1011+HRZ, and HRZ treatment group, respectively (P<0.05).At 8 weeks, the proportion of Masson staining blue-stained area, that was, positive area, in lung tissue was 16.65%±1.82%, 10.01%±2.16%, and 21.36%±3.21%, respectively (F=27.11, P<0.001).The lung injury scores by HE staining at 8 weeks were (5.00±0.50), (5.00±0.47), and (6.89±0.99) points, respectively (F=19.81, P<0.001).The results of 4-week ELISA showed that the levels of TNF-α and IFN-γ in the serum of the SC1011+HRZ-treated group were lower than those of the HRZ-treated group (all P<0.05).The degree of lung injury and fibrosis in PFD+HRZ and SC1011+HRZ treatment groups were lower than those in HRZ treatment group (all P<0.001). The number of viable bacteria in the lung tissue of mice treated with PFD+HRZ, SC1011+HRZ, and HRZ for 4 weeks was lower than that of mice untreated [(1.82±0.10), (1.91±0.05), (1.79±0.17) vs. (5.27±0.07) lg(CFU+1)/ml, all P<0.05)]. And the aseptic transformation of the spleen of mice was achieved in each treatment group at 8 weeks of administration. After 12 weeks of drug withdrawal, the recurrence of lung infection in the SC1011+HRZ treatment group was 3/7 lower than 5/7 in the HRZ treatment group (P>0.05); the recurrence of spleen infection in the SC1011+HRZ treatment group was 1/7 lower than 5/7 in the HRZ treatment group (P>0.05).Pulmonary infection recurred more frequently in PFD+HRZ 6/7 versus HRZ 5/7 (P>0.05). Conclusions: PFD/SC1011, when combined with HRZ, reduced lung injury and reduced secondary fibrosis in pulmonary tuberculosis in C57BL/6 mice. SC1011 combined with HRZ has no significant short-term therapeutic effect on MTB, but may reduce its recurrence rate in long-term treatment, especially in reducing the recurrence rate of mouse spleen.
Collapse
Affiliation(s)
- X T Qi
- Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China
| | - L Y Zheng
- Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China
| | - L Fu
- Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China
| | - W Y Zhang
- Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China
| | - N Wang
- Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China
| | - X Y Chen
- Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - Y Lu
- Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China
| |
Collapse
|
14
|
Ren HY, Fu L, Li Y. Retraction Note to: A New Coordination Polymer Based on Two Dual-Functional Ligands: Structural Insights and Treatment Effect Against Inflammatory Metrorrhagia by Inhibiting NF-κb Activation and IL-1β Release. J STRUCT CHEM+ 2023. [DOI: 10.1134/s0022476623020178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/11/2023]
|
15
|
Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kaźmierczak M, Lamanna N, O'Brien SM, Tam CS, Qiu L, Zhou K, Simkovic M, Mayer J, Gillespie-Twardy A, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, Osterborg A, Yimer HA, Salmi T, Wang MDY, Fu L, Li J, Wu K, Cohen A, Shadman M. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med 2023; 388:319-332. [PMID: 36511784 DOI: 10.1056/nejmoa2211582] [Citation(s) in RCA: 105] [Impact Index Per Article: 105.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
BACKGROUND In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater specificity, as treatment for relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). In prespecified interim analyses, zanubrutinib was superior to ibrutinib with respect to overall response (the primary end point). Data from the final analysis of progression-free survival are now available. METHODS We randomly assigned, in a 1:1 ratio, patients with relapsed or refractory CLL or SLL who had received at least one previous course of therapy to receive zanubrutinib or ibrutinib until the occurrence of disease progression or unacceptable toxic effects. In this final analysis, progression-free survival (a key secondary end point) was assessed with the use of a hierarchical testing strategy to determine whether zanubrutinib was noninferior to ibrutinib. If noninferiority was established, the superiority of zanubrutinib was assessed and claimed if the two-sided P value was less than 0.05. RESULTS At a median follow-up of 29.6 months, zanubrutinib was found to be superior to ibrutinib with respect to progression-free survival among 652 patients (hazard ratio for disease progression or death, 0.65; 95% confidence interval, [CI], 0.49 to 0.86; P = 0.002), as assessed by the investigators; the results were similar to those as assessed by an independent-review committee. At 24 months, the investigator-assessed rates of progression-free survival were 78.4% in the zanubrutinib group and 65.9% in the ibrutinib group. Among patients with a 17p deletion, a TP53 mutation, or both, those who received zanubrutinib had longer progression-free survival than those who received ibrutinib (hazard ratio for disease progression or death, 0.53; 95% CI, 0.31 to 0.88); progression-free survival across other major subgroups consistently favored zanubrutinib. The percentage of patients with an overall response was higher in the zanubrutinib group than in the ibrutinib group. The safety profile of zanubrutinib was better than that of ibrutinib, with fewer adverse events leading to treatment discontinuation and fewer cardiac events, including fewer cardiac events leading to treatment discontinuation or death. CONCLUSIONS In patients with relapsed or refractory CLL or SLL, progression-free survival was significantly longer among patients who received zanubrutinib than among those who received ibrutinib, and zanubrutinib was associated with fewer cardiac adverse events. (Funded by BeiGene; ALPINE ClinicalTrials.gov number, NCT03734016.).
Collapse
Affiliation(s)
- Jennifer R Brown
- From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany (B.E.); St. James's University Hospital, Leeds, United Kingdom (P.H.); Maria Skłodowska-Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the Department of Hematology and Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice (S.G.), the Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk (A.M.), and the Medical University of Lodz, Lodz (T.R.) - all in Poland; Herbert Irving Comprehensive Cancer Center, Columbia University, New York (N.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine (S.M.O.), and BeiGene USA, San Mateo (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - both in California; the Alfred Hospital and Monash University - both in Melbourne, VIC, Australia (C.S.T.); the State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin (L.Q.), the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou (K.Z.), and BeiGene (Beijing), Beijing (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - all in China; the Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove (M. Simkovic), the First Faculty of Medicine, Charles University, Prague (M. Simkovic), and the Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital, Brno (J.M.) - all in the Czech Republic; Blue Ridge Cancer Care, Roanoke, VA (A.G.-T.); the Leukemia Department , University of Texas M.D. Anderson Cancer Center, Houston (A.F.), and Texas Oncology-Tyler, US Oncology Network, Tyler (H.A.Y.) - both in Texas; the Department of Haematology, Christchurch Hospital, Christchurch (P.S.G.), and Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast and Hutt Valley, and the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington (R.W.) - all in New Zealand; the Department of Oncology-Pathology, Karolinska Institutet, and the Department of Hematology, Karolinska University Hospital - both in Stockholm (A.O.); and the Fred Hutchinson Cancer Center and the Department of Medicine, University of Washington - both in Seattle (M. Shadman)
| | - Barbara Eichhorst
- From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany (B.E.); St. James's University Hospital, Leeds, United Kingdom (P.H.); Maria Skłodowska-Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the Department of Hematology and Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice (S.G.), the Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk (A.M.), and the Medical University of Lodz, Lodz (T.R.) - all in Poland; Herbert Irving Comprehensive Cancer Center, Columbia University, New York (N.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine (S.M.O.), and BeiGene USA, San Mateo (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - both in California; the Alfred Hospital and Monash University - both in Melbourne, VIC, Australia (C.S.T.); the State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin (L.Q.), the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou (K.Z.), and BeiGene (Beijing), Beijing (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - all in China; the Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove (M. Simkovic), the First Faculty of Medicine, Charles University, Prague (M. Simkovic), and the Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital, Brno (J.M.) - all in the Czech Republic; Blue Ridge Cancer Care, Roanoke, VA (A.G.-T.); the Leukemia Department , University of Texas M.D. Anderson Cancer Center, Houston (A.F.), and Texas Oncology-Tyler, US Oncology Network, Tyler (H.A.Y.) - both in Texas; the Department of Haematology, Christchurch Hospital, Christchurch (P.S.G.), and Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast and Hutt Valley, and the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington (R.W.) - all in New Zealand; the Department of Oncology-Pathology, Karolinska Institutet, and the Department of Hematology, Karolinska University Hospital - both in Stockholm (A.O.); and the Fred Hutchinson Cancer Center and the Department of Medicine, University of Washington - both in Seattle (M. Shadman)
| | - Peter Hillmen
- From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany (B.E.); St. James's University Hospital, Leeds, United Kingdom (P.H.); Maria Skłodowska-Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the Department of Hematology and Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice (S.G.), the Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk (A.M.), and the Medical University of Lodz, Lodz (T.R.) - all in Poland; Herbert Irving Comprehensive Cancer Center, Columbia University, New York (N.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine (S.M.O.), and BeiGene USA, San Mateo (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - both in California; the Alfred Hospital and Monash University - both in Melbourne, VIC, Australia (C.S.T.); the State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin (L.Q.), the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou (K.Z.), and BeiGene (Beijing), Beijing (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - all in China; the Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove (M. Simkovic), the First Faculty of Medicine, Charles University, Prague (M. Simkovic), and the Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital, Brno (J.M.) - all in the Czech Republic; Blue Ridge Cancer Care, Roanoke, VA (A.G.-T.); the Leukemia Department , University of Texas M.D. Anderson Cancer Center, Houston (A.F.), and Texas Oncology-Tyler, US Oncology Network, Tyler (H.A.Y.) - both in Texas; the Department of Haematology, Christchurch Hospital, Christchurch (P.S.G.), and Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast and Hutt Valley, and the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington (R.W.) - all in New Zealand; the Department of Oncology-Pathology, Karolinska Institutet, and the Department of Hematology, Karolinska University Hospital - both in Stockholm (A.O.); and the Fred Hutchinson Cancer Center and the Department of Medicine, University of Washington - both in Seattle (M. Shadman)
| | - Wojciech Jurczak
- From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany (B.E.); St. James's University Hospital, Leeds, United Kingdom (P.H.); Maria Skłodowska-Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the Department of Hematology and Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice (S.G.), the Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk (A.M.), and the Medical University of Lodz, Lodz (T.R.) - all in Poland; Herbert Irving Comprehensive Cancer Center, Columbia University, New York (N.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine (S.M.O.), and BeiGene USA, San Mateo (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - both in California; the Alfred Hospital and Monash University - both in Melbourne, VIC, Australia (C.S.T.); the State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin (L.Q.), the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou (K.Z.), and BeiGene (Beijing), Beijing (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - all in China; the Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove (M. Simkovic), the First Faculty of Medicine, Charles University, Prague (M. Simkovic), and the Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital, Brno (J.M.) - all in the Czech Republic; Blue Ridge Cancer Care, Roanoke, VA (A.G.-T.); the Leukemia Department , University of Texas M.D. Anderson Cancer Center, Houston (A.F.), and Texas Oncology-Tyler, US Oncology Network, Tyler (H.A.Y.) - both in Texas; the Department of Haematology, Christchurch Hospital, Christchurch (P.S.G.), and Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast and Hutt Valley, and the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington (R.W.) - all in New Zealand; the Department of Oncology-Pathology, Karolinska Institutet, and the Department of Hematology, Karolinska University Hospital - both in Stockholm (A.O.); and the Fred Hutchinson Cancer Center and the Department of Medicine, University of Washington - both in Seattle (M. Shadman)
| | - Maciej Kaźmierczak
- From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany (B.E.); St. James's University Hospital, Leeds, United Kingdom (P.H.); Maria Skłodowska-Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the Department of Hematology and Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice (S.G.), the Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk (A.M.), and the Medical University of Lodz, Lodz (T.R.) - all in Poland; Herbert Irving Comprehensive Cancer Center, Columbia University, New York (N.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine (S.M.O.), and BeiGene USA, San Mateo (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - both in California; the Alfred Hospital and Monash University - both in Melbourne, VIC, Australia (C.S.T.); the State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin (L.Q.), the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou (K.Z.), and BeiGene (Beijing), Beijing (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - all in China; the Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove (M. Simkovic), the First Faculty of Medicine, Charles University, Prague (M. Simkovic), and the Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital, Brno (J.M.) - all in the Czech Republic; Blue Ridge Cancer Care, Roanoke, VA (A.G.-T.); the Leukemia Department , University of Texas M.D. Anderson Cancer Center, Houston (A.F.), and Texas Oncology-Tyler, US Oncology Network, Tyler (H.A.Y.) - both in Texas; the Department of Haematology, Christchurch Hospital, Christchurch (P.S.G.), and Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast and Hutt Valley, and the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington (R.W.) - all in New Zealand; the Department of Oncology-Pathology, Karolinska Institutet, and the Department of Hematology, Karolinska University Hospital - both in Stockholm (A.O.); and the Fred Hutchinson Cancer Center and the Department of Medicine, University of Washington - both in Seattle (M. Shadman)
| | - Nicole Lamanna
- From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany (B.E.); St. James's University Hospital, Leeds, United Kingdom (P.H.); Maria Skłodowska-Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the Department of Hematology and Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice (S.G.), the Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk (A.M.), and the Medical University of Lodz, Lodz (T.R.) - all in Poland; Herbert Irving Comprehensive Cancer Center, Columbia University, New York (N.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine (S.M.O.), and BeiGene USA, San Mateo (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - both in California; the Alfred Hospital and Monash University - both in Melbourne, VIC, Australia (C.S.T.); the State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin (L.Q.), the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou (K.Z.), and BeiGene (Beijing), Beijing (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - all in China; the Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove (M. Simkovic), the First Faculty of Medicine, Charles University, Prague (M. Simkovic), and the Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital, Brno (J.M.) - all in the Czech Republic; Blue Ridge Cancer Care, Roanoke, VA (A.G.-T.); the Leukemia Department , University of Texas M.D. Anderson Cancer Center, Houston (A.F.), and Texas Oncology-Tyler, US Oncology Network, Tyler (H.A.Y.) - both in Texas; the Department of Haematology, Christchurch Hospital, Christchurch (P.S.G.), and Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast and Hutt Valley, and the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington (R.W.) - all in New Zealand; the Department of Oncology-Pathology, Karolinska Institutet, and the Department of Hematology, Karolinska University Hospital - both in Stockholm (A.O.); and the Fred Hutchinson Cancer Center and the Department of Medicine, University of Washington - both in Seattle (M. Shadman)
| | - Susan M O'Brien
- From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany (B.E.); St. James's University Hospital, Leeds, United Kingdom (P.H.); Maria Skłodowska-Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the Department of Hematology and Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice (S.G.), the Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk (A.M.), and the Medical University of Lodz, Lodz (T.R.) - all in Poland; Herbert Irving Comprehensive Cancer Center, Columbia University, New York (N.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine (S.M.O.), and BeiGene USA, San Mateo (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - both in California; the Alfred Hospital and Monash University - both in Melbourne, VIC, Australia (C.S.T.); the State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin (L.Q.), the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou (K.Z.), and BeiGene (Beijing), Beijing (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - all in China; the Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove (M. Simkovic), the First Faculty of Medicine, Charles University, Prague (M. Simkovic), and the Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital, Brno (J.M.) - all in the Czech Republic; Blue Ridge Cancer Care, Roanoke, VA (A.G.-T.); the Leukemia Department , University of Texas M.D. Anderson Cancer Center, Houston (A.F.), and Texas Oncology-Tyler, US Oncology Network, Tyler (H.A.Y.) - both in Texas; the Department of Haematology, Christchurch Hospital, Christchurch (P.S.G.), and Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast and Hutt Valley, and the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington (R.W.) - all in New Zealand; the Department of Oncology-Pathology, Karolinska Institutet, and the Department of Hematology, Karolinska University Hospital - both in Stockholm (A.O.); and the Fred Hutchinson Cancer Center and the Department of Medicine, University of Washington - both in Seattle (M. Shadman)
| | - Constantine S Tam
- From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany (B.E.); St. James's University Hospital, Leeds, United Kingdom (P.H.); Maria Skłodowska-Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the Department of Hematology and Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice (S.G.), the Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk (A.M.), and the Medical University of Lodz, Lodz (T.R.) - all in Poland; Herbert Irving Comprehensive Cancer Center, Columbia University, New York (N.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine (S.M.O.), and BeiGene USA, San Mateo (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - both in California; the Alfred Hospital and Monash University - both in Melbourne, VIC, Australia (C.S.T.); the State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin (L.Q.), the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou (K.Z.), and BeiGene (Beijing), Beijing (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - all in China; the Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove (M. Simkovic), the First Faculty of Medicine, Charles University, Prague (M. Simkovic), and the Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital, Brno (J.M.) - all in the Czech Republic; Blue Ridge Cancer Care, Roanoke, VA (A.G.-T.); the Leukemia Department , University of Texas M.D. Anderson Cancer Center, Houston (A.F.), and Texas Oncology-Tyler, US Oncology Network, Tyler (H.A.Y.) - both in Texas; the Department of Haematology, Christchurch Hospital, Christchurch (P.S.G.), and Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast and Hutt Valley, and the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington (R.W.) - all in New Zealand; the Department of Oncology-Pathology, Karolinska Institutet, and the Department of Hematology, Karolinska University Hospital - both in Stockholm (A.O.); and the Fred Hutchinson Cancer Center and the Department of Medicine, University of Washington - both in Seattle (M. Shadman)
| | - Lugui Qiu
- From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany (B.E.); St. James's University Hospital, Leeds, United Kingdom (P.H.); Maria Skłodowska-Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the Department of Hematology and Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice (S.G.), the Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk (A.M.), and the Medical University of Lodz, Lodz (T.R.) - all in Poland; Herbert Irving Comprehensive Cancer Center, Columbia University, New York (N.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine (S.M.O.), and BeiGene USA, San Mateo (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - both in California; the Alfred Hospital and Monash University - both in Melbourne, VIC, Australia (C.S.T.); the State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin (L.Q.), the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou (K.Z.), and BeiGene (Beijing), Beijing (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - all in China; the Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove (M. Simkovic), the First Faculty of Medicine, Charles University, Prague (M. Simkovic), and the Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital, Brno (J.M.) - all in the Czech Republic; Blue Ridge Cancer Care, Roanoke, VA (A.G.-T.); the Leukemia Department , University of Texas M.D. Anderson Cancer Center, Houston (A.F.), and Texas Oncology-Tyler, US Oncology Network, Tyler (H.A.Y.) - both in Texas; the Department of Haematology, Christchurch Hospital, Christchurch (P.S.G.), and Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast and Hutt Valley, and the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington (R.W.) - all in New Zealand; the Department of Oncology-Pathology, Karolinska Institutet, and the Department of Hematology, Karolinska University Hospital - both in Stockholm (A.O.); and the Fred Hutchinson Cancer Center and the Department of Medicine, University of Washington - both in Seattle (M. Shadman)
| | - Keshu Zhou
- From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany (B.E.); St. James's University Hospital, Leeds, United Kingdom (P.H.); Maria Skłodowska-Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the Department of Hematology and Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice (S.G.), the Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk (A.M.), and the Medical University of Lodz, Lodz (T.R.) - all in Poland; Herbert Irving Comprehensive Cancer Center, Columbia University, New York (N.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine (S.M.O.), and BeiGene USA, San Mateo (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - both in California; the Alfred Hospital and Monash University - both in Melbourne, VIC, Australia (C.S.T.); the State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin (L.Q.), the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou (K.Z.), and BeiGene (Beijing), Beijing (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - all in China; the Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove (M. Simkovic), the First Faculty of Medicine, Charles University, Prague (M. Simkovic), and the Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital, Brno (J.M.) - all in the Czech Republic; Blue Ridge Cancer Care, Roanoke, VA (A.G.-T.); the Leukemia Department , University of Texas M.D. Anderson Cancer Center, Houston (A.F.), and Texas Oncology-Tyler, US Oncology Network, Tyler (H.A.Y.) - both in Texas; the Department of Haematology, Christchurch Hospital, Christchurch (P.S.G.), and Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast and Hutt Valley, and the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington (R.W.) - all in New Zealand; the Department of Oncology-Pathology, Karolinska Institutet, and the Department of Hematology, Karolinska University Hospital - both in Stockholm (A.O.); and the Fred Hutchinson Cancer Center and the Department of Medicine, University of Washington - both in Seattle (M. Shadman)
| | - Martin Simkovic
- From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany (B.E.); St. James's University Hospital, Leeds, United Kingdom (P.H.); Maria Skłodowska-Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the Department of Hematology and Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice (S.G.), the Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk (A.M.), and the Medical University of Lodz, Lodz (T.R.) - all in Poland; Herbert Irving Comprehensive Cancer Center, Columbia University, New York (N.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine (S.M.O.), and BeiGene USA, San Mateo (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - both in California; the Alfred Hospital and Monash University - both in Melbourne, VIC, Australia (C.S.T.); the State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin (L.Q.), the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou (K.Z.), and BeiGene (Beijing), Beijing (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - all in China; the Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove (M. Simkovic), the First Faculty of Medicine, Charles University, Prague (M. Simkovic), and the Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital, Brno (J.M.) - all in the Czech Republic; Blue Ridge Cancer Care, Roanoke, VA (A.G.-T.); the Leukemia Department , University of Texas M.D. Anderson Cancer Center, Houston (A.F.), and Texas Oncology-Tyler, US Oncology Network, Tyler (H.A.Y.) - both in Texas; the Department of Haematology, Christchurch Hospital, Christchurch (P.S.G.), and Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast and Hutt Valley, and the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington (R.W.) - all in New Zealand; the Department of Oncology-Pathology, Karolinska Institutet, and the Department of Hematology, Karolinska University Hospital - both in Stockholm (A.O.); and the Fred Hutchinson Cancer Center and the Department of Medicine, University of Washington - both in Seattle (M. Shadman)
| | - Jiri Mayer
- From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany (B.E.); St. James's University Hospital, Leeds, United Kingdom (P.H.); Maria Skłodowska-Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the Department of Hematology and Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice (S.G.), the Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk (A.M.), and the Medical University of Lodz, Lodz (T.R.) - all in Poland; Herbert Irving Comprehensive Cancer Center, Columbia University, New York (N.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine (S.M.O.), and BeiGene USA, San Mateo (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - both in California; the Alfred Hospital and Monash University - both in Melbourne, VIC, Australia (C.S.T.); the State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin (L.Q.), the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou (K.Z.), and BeiGene (Beijing), Beijing (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - all in China; the Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove (M. Simkovic), the First Faculty of Medicine, Charles University, Prague (M. Simkovic), and the Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital, Brno (J.M.) - all in the Czech Republic; Blue Ridge Cancer Care, Roanoke, VA (A.G.-T.); the Leukemia Department , University of Texas M.D. Anderson Cancer Center, Houston (A.F.), and Texas Oncology-Tyler, US Oncology Network, Tyler (H.A.Y.) - both in Texas; the Department of Haematology, Christchurch Hospital, Christchurch (P.S.G.), and Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast and Hutt Valley, and the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington (R.W.) - all in New Zealand; the Department of Oncology-Pathology, Karolinska Institutet, and the Department of Hematology, Karolinska University Hospital - both in Stockholm (A.O.); and the Fred Hutchinson Cancer Center and the Department of Medicine, University of Washington - both in Seattle (M. Shadman)
| | - Amanda Gillespie-Twardy
- From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany (B.E.); St. James's University Hospital, Leeds, United Kingdom (P.H.); Maria Skłodowska-Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the Department of Hematology and Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice (S.G.), the Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk (A.M.), and the Medical University of Lodz, Lodz (T.R.) - all in Poland; Herbert Irving Comprehensive Cancer Center, Columbia University, New York (N.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine (S.M.O.), and BeiGene USA, San Mateo (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - both in California; the Alfred Hospital and Monash University - both in Melbourne, VIC, Australia (C.S.T.); the State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin (L.Q.), the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou (K.Z.), and BeiGene (Beijing), Beijing (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - all in China; the Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove (M. Simkovic), the First Faculty of Medicine, Charles University, Prague (M. Simkovic), and the Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital, Brno (J.M.) - all in the Czech Republic; Blue Ridge Cancer Care, Roanoke, VA (A.G.-T.); the Leukemia Department , University of Texas M.D. Anderson Cancer Center, Houston (A.F.), and Texas Oncology-Tyler, US Oncology Network, Tyler (H.A.Y.) - both in Texas; the Department of Haematology, Christchurch Hospital, Christchurch (P.S.G.), and Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast and Hutt Valley, and the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington (R.W.) - all in New Zealand; the Department of Oncology-Pathology, Karolinska Institutet, and the Department of Hematology, Karolinska University Hospital - both in Stockholm (A.O.); and the Fred Hutchinson Cancer Center and the Department of Medicine, University of Washington - both in Seattle (M. Shadman)
| | - Alessandra Ferrajoli
- From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany (B.E.); St. James's University Hospital, Leeds, United Kingdom (P.H.); Maria Skłodowska-Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the Department of Hematology and Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice (S.G.), the Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk (A.M.), and the Medical University of Lodz, Lodz (T.R.) - all in Poland; Herbert Irving Comprehensive Cancer Center, Columbia University, New York (N.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine (S.M.O.), and BeiGene USA, San Mateo (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - both in California; the Alfred Hospital and Monash University - both in Melbourne, VIC, Australia (C.S.T.); the State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin (L.Q.), the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou (K.Z.), and BeiGene (Beijing), Beijing (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - all in China; the Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove (M. Simkovic), the First Faculty of Medicine, Charles University, Prague (M. Simkovic), and the Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital, Brno (J.M.) - all in the Czech Republic; Blue Ridge Cancer Care, Roanoke, VA (A.G.-T.); the Leukemia Department , University of Texas M.D. Anderson Cancer Center, Houston (A.F.), and Texas Oncology-Tyler, US Oncology Network, Tyler (H.A.Y.) - both in Texas; the Department of Haematology, Christchurch Hospital, Christchurch (P.S.G.), and Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast and Hutt Valley, and the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington (R.W.) - all in New Zealand; the Department of Oncology-Pathology, Karolinska Institutet, and the Department of Hematology, Karolinska University Hospital - both in Stockholm (A.O.); and the Fred Hutchinson Cancer Center and the Department of Medicine, University of Washington - both in Seattle (M. Shadman)
| | - Peter S Ganly
- From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany (B.E.); St. James's University Hospital, Leeds, United Kingdom (P.H.); Maria Skłodowska-Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the Department of Hematology and Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice (S.G.), the Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk (A.M.), and the Medical University of Lodz, Lodz (T.R.) - all in Poland; Herbert Irving Comprehensive Cancer Center, Columbia University, New York (N.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine (S.M.O.), and BeiGene USA, San Mateo (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - both in California; the Alfred Hospital and Monash University - both in Melbourne, VIC, Australia (C.S.T.); the State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin (L.Q.), the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou (K.Z.), and BeiGene (Beijing), Beijing (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - all in China; the Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove (M. Simkovic), the First Faculty of Medicine, Charles University, Prague (M. Simkovic), and the Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital, Brno (J.M.) - all in the Czech Republic; Blue Ridge Cancer Care, Roanoke, VA (A.G.-T.); the Leukemia Department , University of Texas M.D. Anderson Cancer Center, Houston (A.F.), and Texas Oncology-Tyler, US Oncology Network, Tyler (H.A.Y.) - both in Texas; the Department of Haematology, Christchurch Hospital, Christchurch (P.S.G.), and Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast and Hutt Valley, and the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington (R.W.) - all in New Zealand; the Department of Oncology-Pathology, Karolinska Institutet, and the Department of Hematology, Karolinska University Hospital - both in Stockholm (A.O.); and the Fred Hutchinson Cancer Center and the Department of Medicine, University of Washington - both in Seattle (M. Shadman)
| | - Robert Weinkove
- From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany (B.E.); St. James's University Hospital, Leeds, United Kingdom (P.H.); Maria Skłodowska-Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the Department of Hematology and Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice (S.G.), the Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk (A.M.), and the Medical University of Lodz, Lodz (T.R.) - all in Poland; Herbert Irving Comprehensive Cancer Center, Columbia University, New York (N.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine (S.M.O.), and BeiGene USA, San Mateo (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - both in California; the Alfred Hospital and Monash University - both in Melbourne, VIC, Australia (C.S.T.); the State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin (L.Q.), the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou (K.Z.), and BeiGene (Beijing), Beijing (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - all in China; the Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove (M. Simkovic), the First Faculty of Medicine, Charles University, Prague (M. Simkovic), and the Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital, Brno (J.M.) - all in the Czech Republic; Blue Ridge Cancer Care, Roanoke, VA (A.G.-T.); the Leukemia Department , University of Texas M.D. Anderson Cancer Center, Houston (A.F.), and Texas Oncology-Tyler, US Oncology Network, Tyler (H.A.Y.) - both in Texas; the Department of Haematology, Christchurch Hospital, Christchurch (P.S.G.), and Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast and Hutt Valley, and the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington (R.W.) - all in New Zealand; the Department of Oncology-Pathology, Karolinska Institutet, and the Department of Hematology, Karolinska University Hospital - both in Stockholm (A.O.); and the Fred Hutchinson Cancer Center and the Department of Medicine, University of Washington - both in Seattle (M. Shadman)
| | - Sebastian Grosicki
- From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany (B.E.); St. James's University Hospital, Leeds, United Kingdom (P.H.); Maria Skłodowska-Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the Department of Hematology and Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice (S.G.), the Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk (A.M.), and the Medical University of Lodz, Lodz (T.R.) - all in Poland; Herbert Irving Comprehensive Cancer Center, Columbia University, New York (N.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine (S.M.O.), and BeiGene USA, San Mateo (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - both in California; the Alfred Hospital and Monash University - both in Melbourne, VIC, Australia (C.S.T.); the State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin (L.Q.), the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou (K.Z.), and BeiGene (Beijing), Beijing (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - all in China; the Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove (M. Simkovic), the First Faculty of Medicine, Charles University, Prague (M. Simkovic), and the Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital, Brno (J.M.) - all in the Czech Republic; Blue Ridge Cancer Care, Roanoke, VA (A.G.-T.); the Leukemia Department , University of Texas M.D. Anderson Cancer Center, Houston (A.F.), and Texas Oncology-Tyler, US Oncology Network, Tyler (H.A.Y.) - both in Texas; the Department of Haematology, Christchurch Hospital, Christchurch (P.S.G.), and Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast and Hutt Valley, and the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington (R.W.) - all in New Zealand; the Department of Oncology-Pathology, Karolinska Institutet, and the Department of Hematology, Karolinska University Hospital - both in Stockholm (A.O.); and the Fred Hutchinson Cancer Center and the Department of Medicine, University of Washington - both in Seattle (M. Shadman)
| | - Andrzej Mital
- From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany (B.E.); St. James's University Hospital, Leeds, United Kingdom (P.H.); Maria Skłodowska-Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the Department of Hematology and Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice (S.G.), the Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk (A.M.), and the Medical University of Lodz, Lodz (T.R.) - all in Poland; Herbert Irving Comprehensive Cancer Center, Columbia University, New York (N.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine (S.M.O.), and BeiGene USA, San Mateo (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - both in California; the Alfred Hospital and Monash University - both in Melbourne, VIC, Australia (C.S.T.); the State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin (L.Q.), the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou (K.Z.), and BeiGene (Beijing), Beijing (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - all in China; the Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove (M. Simkovic), the First Faculty of Medicine, Charles University, Prague (M. Simkovic), and the Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital, Brno (J.M.) - all in the Czech Republic; Blue Ridge Cancer Care, Roanoke, VA (A.G.-T.); the Leukemia Department , University of Texas M.D. Anderson Cancer Center, Houston (A.F.), and Texas Oncology-Tyler, US Oncology Network, Tyler (H.A.Y.) - both in Texas; the Department of Haematology, Christchurch Hospital, Christchurch (P.S.G.), and Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast and Hutt Valley, and the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington (R.W.) - all in New Zealand; the Department of Oncology-Pathology, Karolinska Institutet, and the Department of Hematology, Karolinska University Hospital - both in Stockholm (A.O.); and the Fred Hutchinson Cancer Center and the Department of Medicine, University of Washington - both in Seattle (M. Shadman)
| | - Tadeusz Robak
- From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany (B.E.); St. James's University Hospital, Leeds, United Kingdom (P.H.); Maria Skłodowska-Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the Department of Hematology and Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice (S.G.), the Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk (A.M.), and the Medical University of Lodz, Lodz (T.R.) - all in Poland; Herbert Irving Comprehensive Cancer Center, Columbia University, New York (N.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine (S.M.O.), and BeiGene USA, San Mateo (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - both in California; the Alfred Hospital and Monash University - both in Melbourne, VIC, Australia (C.S.T.); the State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin (L.Q.), the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou (K.Z.), and BeiGene (Beijing), Beijing (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - all in China; the Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove (M. Simkovic), the First Faculty of Medicine, Charles University, Prague (M. Simkovic), and the Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital, Brno (J.M.) - all in the Czech Republic; Blue Ridge Cancer Care, Roanoke, VA (A.G.-T.); the Leukemia Department , University of Texas M.D. Anderson Cancer Center, Houston (A.F.), and Texas Oncology-Tyler, US Oncology Network, Tyler (H.A.Y.) - both in Texas; the Department of Haematology, Christchurch Hospital, Christchurch (P.S.G.), and Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast and Hutt Valley, and the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington (R.W.) - all in New Zealand; the Department of Oncology-Pathology, Karolinska Institutet, and the Department of Hematology, Karolinska University Hospital - both in Stockholm (A.O.); and the Fred Hutchinson Cancer Center and the Department of Medicine, University of Washington - both in Seattle (M. Shadman)
| | - Anders Osterborg
- From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany (B.E.); St. James's University Hospital, Leeds, United Kingdom (P.H.); Maria Skłodowska-Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the Department of Hematology and Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice (S.G.), the Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk (A.M.), and the Medical University of Lodz, Lodz (T.R.) - all in Poland; Herbert Irving Comprehensive Cancer Center, Columbia University, New York (N.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine (S.M.O.), and BeiGene USA, San Mateo (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - both in California; the Alfred Hospital and Monash University - both in Melbourne, VIC, Australia (C.S.T.); the State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin (L.Q.), the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou (K.Z.), and BeiGene (Beijing), Beijing (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - all in China; the Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove (M. Simkovic), the First Faculty of Medicine, Charles University, Prague (M. Simkovic), and the Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital, Brno (J.M.) - all in the Czech Republic; Blue Ridge Cancer Care, Roanoke, VA (A.G.-T.); the Leukemia Department , University of Texas M.D. Anderson Cancer Center, Houston (A.F.), and Texas Oncology-Tyler, US Oncology Network, Tyler (H.A.Y.) - both in Texas; the Department of Haematology, Christchurch Hospital, Christchurch (P.S.G.), and Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast and Hutt Valley, and the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington (R.W.) - all in New Zealand; the Department of Oncology-Pathology, Karolinska Institutet, and the Department of Hematology, Karolinska University Hospital - both in Stockholm (A.O.); and the Fred Hutchinson Cancer Center and the Department of Medicine, University of Washington - both in Seattle (M. Shadman)
| | - Habte A Yimer
- From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany (B.E.); St. James's University Hospital, Leeds, United Kingdom (P.H.); Maria Skłodowska-Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the Department of Hematology and Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice (S.G.), the Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk (A.M.), and the Medical University of Lodz, Lodz (T.R.) - all in Poland; Herbert Irving Comprehensive Cancer Center, Columbia University, New York (N.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine (S.M.O.), and BeiGene USA, San Mateo (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - both in California; the Alfred Hospital and Monash University - both in Melbourne, VIC, Australia (C.S.T.); the State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin (L.Q.), the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou (K.Z.), and BeiGene (Beijing), Beijing (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - all in China; the Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove (M. Simkovic), the First Faculty of Medicine, Charles University, Prague (M. Simkovic), and the Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital, Brno (J.M.) - all in the Czech Republic; Blue Ridge Cancer Care, Roanoke, VA (A.G.-T.); the Leukemia Department , University of Texas M.D. Anderson Cancer Center, Houston (A.F.), and Texas Oncology-Tyler, US Oncology Network, Tyler (H.A.Y.) - both in Texas; the Department of Haematology, Christchurch Hospital, Christchurch (P.S.G.), and Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast and Hutt Valley, and the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington (R.W.) - all in New Zealand; the Department of Oncology-Pathology, Karolinska Institutet, and the Department of Hematology, Karolinska University Hospital - both in Stockholm (A.O.); and the Fred Hutchinson Cancer Center and the Department of Medicine, University of Washington - both in Seattle (M. Shadman)
| | - Tommi Salmi
- From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany (B.E.); St. James's University Hospital, Leeds, United Kingdom (P.H.); Maria Skłodowska-Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the Department of Hematology and Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice (S.G.), the Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk (A.M.), and the Medical University of Lodz, Lodz (T.R.) - all in Poland; Herbert Irving Comprehensive Cancer Center, Columbia University, New York (N.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine (S.M.O.), and BeiGene USA, San Mateo (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - both in California; the Alfred Hospital and Monash University - both in Melbourne, VIC, Australia (C.S.T.); the State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin (L.Q.), the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou (K.Z.), and BeiGene (Beijing), Beijing (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - all in China; the Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove (M. Simkovic), the First Faculty of Medicine, Charles University, Prague (M. Simkovic), and the Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital, Brno (J.M.) - all in the Czech Republic; Blue Ridge Cancer Care, Roanoke, VA (A.G.-T.); the Leukemia Department , University of Texas M.D. Anderson Cancer Center, Houston (A.F.), and Texas Oncology-Tyler, US Oncology Network, Tyler (H.A.Y.) - both in Texas; the Department of Haematology, Christchurch Hospital, Christchurch (P.S.G.), and Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast and Hutt Valley, and the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington (R.W.) - all in New Zealand; the Department of Oncology-Pathology, Karolinska Institutet, and the Department of Hematology, Karolinska University Hospital - both in Stockholm (A.O.); and the Fred Hutchinson Cancer Center and the Department of Medicine, University of Washington - both in Seattle (M. Shadman)
| | - Megan-Der-Yu Wang
- From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany (B.E.); St. James's University Hospital, Leeds, United Kingdom (P.H.); Maria Skłodowska-Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the Department of Hematology and Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice (S.G.), the Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk (A.M.), and the Medical University of Lodz, Lodz (T.R.) - all in Poland; Herbert Irving Comprehensive Cancer Center, Columbia University, New York (N.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine (S.M.O.), and BeiGene USA, San Mateo (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - both in California; the Alfred Hospital and Monash University - both in Melbourne, VIC, Australia (C.S.T.); the State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin (L.Q.), the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou (K.Z.), and BeiGene (Beijing), Beijing (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - all in China; the Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove (M. Simkovic), the First Faculty of Medicine, Charles University, Prague (M. Simkovic), and the Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital, Brno (J.M.) - all in the Czech Republic; Blue Ridge Cancer Care, Roanoke, VA (A.G.-T.); the Leukemia Department , University of Texas M.D. Anderson Cancer Center, Houston (A.F.), and Texas Oncology-Tyler, US Oncology Network, Tyler (H.A.Y.) - both in Texas; the Department of Haematology, Christchurch Hospital, Christchurch (P.S.G.), and Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast and Hutt Valley, and the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington (R.W.) - all in New Zealand; the Department of Oncology-Pathology, Karolinska Institutet, and the Department of Hematology, Karolinska University Hospital - both in Stockholm (A.O.); and the Fred Hutchinson Cancer Center and the Department of Medicine, University of Washington - both in Seattle (M. Shadman)
| | - Lina Fu
- From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany (B.E.); St. James's University Hospital, Leeds, United Kingdom (P.H.); Maria Skłodowska-Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the Department of Hematology and Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice (S.G.), the Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk (A.M.), and the Medical University of Lodz, Lodz (T.R.) - all in Poland; Herbert Irving Comprehensive Cancer Center, Columbia University, New York (N.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine (S.M.O.), and BeiGene USA, San Mateo (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - both in California; the Alfred Hospital and Monash University - both in Melbourne, VIC, Australia (C.S.T.); the State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin (L.Q.), the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou (K.Z.), and BeiGene (Beijing), Beijing (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - all in China; the Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove (M. Simkovic), the First Faculty of Medicine, Charles University, Prague (M. Simkovic), and the Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital, Brno (J.M.) - all in the Czech Republic; Blue Ridge Cancer Care, Roanoke, VA (A.G.-T.); the Leukemia Department , University of Texas M.D. Anderson Cancer Center, Houston (A.F.), and Texas Oncology-Tyler, US Oncology Network, Tyler (H.A.Y.) - both in Texas; the Department of Haematology, Christchurch Hospital, Christchurch (P.S.G.), and Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast and Hutt Valley, and the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington (R.W.) - all in New Zealand; the Department of Oncology-Pathology, Karolinska Institutet, and the Department of Hematology, Karolinska University Hospital - both in Stockholm (A.O.); and the Fred Hutchinson Cancer Center and the Department of Medicine, University of Washington - both in Seattle (M. Shadman)
| | - Jessica Li
- From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany (B.E.); St. James's University Hospital, Leeds, United Kingdom (P.H.); Maria Skłodowska-Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the Department of Hematology and Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice (S.G.), the Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk (A.M.), and the Medical University of Lodz, Lodz (T.R.) - all in Poland; Herbert Irving Comprehensive Cancer Center, Columbia University, New York (N.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine (S.M.O.), and BeiGene USA, San Mateo (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - both in California; the Alfred Hospital and Monash University - both in Melbourne, VIC, Australia (C.S.T.); the State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin (L.Q.), the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou (K.Z.), and BeiGene (Beijing), Beijing (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - all in China; the Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove (M. Simkovic), the First Faculty of Medicine, Charles University, Prague (M. Simkovic), and the Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital, Brno (J.M.) - all in the Czech Republic; Blue Ridge Cancer Care, Roanoke, VA (A.G.-T.); the Leukemia Department , University of Texas M.D. Anderson Cancer Center, Houston (A.F.), and Texas Oncology-Tyler, US Oncology Network, Tyler (H.A.Y.) - both in Texas; the Department of Haematology, Christchurch Hospital, Christchurch (P.S.G.), and Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast and Hutt Valley, and the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington (R.W.) - all in New Zealand; the Department of Oncology-Pathology, Karolinska Institutet, and the Department of Hematology, Karolinska University Hospital - both in Stockholm (A.O.); and the Fred Hutchinson Cancer Center and the Department of Medicine, University of Washington - both in Seattle (M. Shadman)
| | - Kenneth Wu
- From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany (B.E.); St. James's University Hospital, Leeds, United Kingdom (P.H.); Maria Skłodowska-Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the Department of Hematology and Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice (S.G.), the Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk (A.M.), and the Medical University of Lodz, Lodz (T.R.) - all in Poland; Herbert Irving Comprehensive Cancer Center, Columbia University, New York (N.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine (S.M.O.), and BeiGene USA, San Mateo (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - both in California; the Alfred Hospital and Monash University - both in Melbourne, VIC, Australia (C.S.T.); the State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin (L.Q.), the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou (K.Z.), and BeiGene (Beijing), Beijing (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - all in China; the Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove (M. Simkovic), the First Faculty of Medicine, Charles University, Prague (M. Simkovic), and the Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital, Brno (J.M.) - all in the Czech Republic; Blue Ridge Cancer Care, Roanoke, VA (A.G.-T.); the Leukemia Department , University of Texas M.D. Anderson Cancer Center, Houston (A.F.), and Texas Oncology-Tyler, US Oncology Network, Tyler (H.A.Y.) - both in Texas; the Department of Haematology, Christchurch Hospital, Christchurch (P.S.G.), and Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast and Hutt Valley, and the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington (R.W.) - all in New Zealand; the Department of Oncology-Pathology, Karolinska Institutet, and the Department of Hematology, Karolinska University Hospital - both in Stockholm (A.O.); and the Fred Hutchinson Cancer Center and the Department of Medicine, University of Washington - both in Seattle (M. Shadman)
| | - Aileen Cohen
- From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany (B.E.); St. James's University Hospital, Leeds, United Kingdom (P.H.); Maria Skłodowska-Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the Department of Hematology and Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice (S.G.), the Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk (A.M.), and the Medical University of Lodz, Lodz (T.R.) - all in Poland; Herbert Irving Comprehensive Cancer Center, Columbia University, New York (N.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine (S.M.O.), and BeiGene USA, San Mateo (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - both in California; the Alfred Hospital and Monash University - both in Melbourne, VIC, Australia (C.S.T.); the State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin (L.Q.), the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou (K.Z.), and BeiGene (Beijing), Beijing (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - all in China; the Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove (M. Simkovic), the First Faculty of Medicine, Charles University, Prague (M. Simkovic), and the Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital, Brno (J.M.) - all in the Czech Republic; Blue Ridge Cancer Care, Roanoke, VA (A.G.-T.); the Leukemia Department , University of Texas M.D. Anderson Cancer Center, Houston (A.F.), and Texas Oncology-Tyler, US Oncology Network, Tyler (H.A.Y.) - both in Texas; the Department of Haematology, Christchurch Hospital, Christchurch (P.S.G.), and Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast and Hutt Valley, and the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington (R.W.) - all in New Zealand; the Department of Oncology-Pathology, Karolinska Institutet, and the Department of Hematology, Karolinska University Hospital - both in Stockholm (A.O.); and the Fred Hutchinson Cancer Center and the Department of Medicine, University of Washington - both in Seattle (M. Shadman)
| | - Mazyar Shadman
- From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany (B.E.); St. James's University Hospital, Leeds, United Kingdom (P.H.); Maria Skłodowska-Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the Department of Hematology and Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice (S.G.), the Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk (A.M.), and the Medical University of Lodz, Lodz (T.R.) - all in Poland; Herbert Irving Comprehensive Cancer Center, Columbia University, New York (N.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine (S.M.O.), and BeiGene USA, San Mateo (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - both in California; the Alfred Hospital and Monash University - both in Melbourne, VIC, Australia (C.S.T.); the State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin (L.Q.), the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou (K.Z.), and BeiGene (Beijing), Beijing (T.S., M.-D.-Y.W., L.F., J.L., K.W., A.C.) - all in China; the Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove (M. Simkovic), the First Faculty of Medicine, Charles University, Prague (M. Simkovic), and the Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital, Brno (J.M.) - all in the Czech Republic; Blue Ridge Cancer Care, Roanoke, VA (A.G.-T.); the Leukemia Department , University of Texas M.D. Anderson Cancer Center, Houston (A.F.), and Texas Oncology-Tyler, US Oncology Network, Tyler (H.A.Y.) - both in Texas; the Department of Haematology, Christchurch Hospital, Christchurch (P.S.G.), and Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast and Hutt Valley, and the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington (R.W.) - all in New Zealand; the Department of Oncology-Pathology, Karolinska Institutet, and the Department of Hematology, Karolinska University Hospital - both in Stockholm (A.O.); and the Fred Hutchinson Cancer Center and the Department of Medicine, University of Washington - both in Seattle (M. Shadman)
| |
Collapse
|
16
|
Xue T, Fan X, Cao H, Fu L. A periodic boundary value problem of fractional differential equation involving p(t)-Laplacian operator. Math Biosci Eng 2023; 20:4421-4436. [PMID: 36896506 DOI: 10.3934/mbe.2023205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/18/2023]
Abstract
The purpose of this article is to research the existence of solutions for fractional periodic boundary value problems with p(t)-Laplacian operator. In this regard, the article needs to establish a continuation theorem corresponding to the above problem. By applying the continuation theorem, a new existence result for the problem is obtained, which enriches existing literature. In addition, we provide an example to verify the main result.
Collapse
Affiliation(s)
- Tingting Xue
- School of Mathematics and Physics, Xinjiang Institute of Engineering, Urumqi, Xinjiang, China
| | - Xiaolin Fan
- School of Mathematics and Physics, Xinjiang Institute of Engineering, Urumqi, Xinjiang, China
| | - Hong Cao
- College of Mathematics and System Science, Xinjiang University, Urumqi, Xinjiang, China
| | - Lina Fu
- School of Mathematics and Physics, Xinjiang Institute of Engineering, Urumqi, Xinjiang, China
| |
Collapse
|
17
|
Fu L, Yi Y, Wu T, Cheng R, Zhang Z. Do carbon emission trading scheme policies induce green technology innovation? New evidence from provincial green patents in China. Environ Sci Pollut Res Int 2023; 30:13342-13358. [PMID: 36129650 DOI: 10.1007/s11356-022-22877-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/11/2022] [Accepted: 08/31/2022] [Indexed: 06/15/2023]
Abstract
Carbon emission trading scheme (ETS) policy is a quota-based market-motivated environmental regulation policy that by transforming environmental responsibility of enterprises into self-consciousness behavior induces green innovation behavior in enterprises and influences the level of regional green innovation. Based on panel data on green patents in 30 Chinese provinces from 2010 to 2019, the paper uses six Chinese pilot provinces for ETS as the treatment group to investigate the induced effects of Chinese ETS policy on the quantity and quality of green technology innovation using difference in difference model and analyzes the effects of Chinese ETS policy on green technology innovation in different pilot regions using a synthetic control method. The findings indicate that (1) compared with non-pilot areas, the carbon emission trading policies in pilot areas can induce green technology innovation activities. (2) In all pilot regions, ETS policies significantly promoted the quantity and quality of green technology innovation, but the quantity promotion effect was significantly better than the quality promotion effect, and the low-quality promotion effect was better than the high-quality promotion effect. (3) In terms of individual pilot region, ETS policies in Guangdong, Hubei and Tianjin significantly promoted the quantity of green technology innovation and low-quality green technology innovation, but significantly inhibited or suppressed high-quality green technology innovation in a short term. This paper not only enriches the research on environmental equity trading policies and green technology innovation theoretically, but also provides empirical evidence for the effectiveness of carbon emission trading schemes pilots program in China.
Collapse
Affiliation(s)
- Lina Fu
- School of Public Administration, China University of Geosciences, Wuhan, 430074, China
| | - Yang Yi
- School of Economics and Management, China University of Geosciences, Wuhan, 430074, China.
| | - Ting Wu
- School of Marxism, China University of Geosciences, Wuhan, 430074, China
| | - Ruiwen Cheng
- Shanghai Jiao Tong University, Shanghai, 200240, China
| | - Zuoming Zhang
- Accounting College, Wuhan Textile University, Wuhan, 430200, China
| |
Collapse
|
18
|
Fu L, Gilham D, Stotz S, Sarsons C, Rakai B, Tsujikawa L, Wasiak S, Johansson J, Sweeney M, Wong N, Kulikowski E. Apabetalone, a BET inhibitor, attenuates inflammation induced by viral RNA mimetic and reduces SARS-CoV-2 spike protein binding regardless of variants. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background/Introduction
Hyperinflammatory responses to SARS-CoV-2 can cause myocarditis and cardiac dysfunction including congestive heart failure [1]. SARS-CoV-2 RNA induces type I interferon (IFN-I), activating IFN regulatory factors (IRFs) and downstream IFN stimulated genes (ISGs) to initiate inflammatory processes. SARS-CoV-2 variants may develop immune escape, undercutting benefits of vaccinations. These challenges highlight the need of variant-independent therapies to improve COVID-19 outcomes. Apabetalone is an epigenetic BD2-selective BET inhibitor in phase 3 trials for cardiovascular disease [2]. Apabetalone has the potential to treat COVID-19. It counters inflammatory signals caused by cytokine storm (CS), preventing cardiac dysfunction associated with severe COVID-19 symptoms in cardiac organoids [3]. It also downregulates angiotensin-converting enzyme 2 (ACE2) expression, the main host cell receptor for SARS-CoV-2 spike protein thus impeding propagation of wild-type SARS-CoV-2 [3,4].
Purpose
1) Evaluate apabetalone's effect on inflammatory processes induced by viral-RNA mimetic in human lung cells; 2) Assess apabetalone's ability to prevent binding of the highly contagious delta variant spike protein to human lung cells.
Methods
Inflammatory gene expression was examined by real-time PCR in apabetalone treated human bronchial epithelial cells (Calu-3) stimulated with poly I:C, a well-accepted viral RNA mimetic that elicits inflammatory signals similar to SARS-CoV-2 RNA [5]. Binding of SARS-CoV-2 delta or wild-type spike protein to apabetalone treated Calu-3 cells was determined by flow cytometry.
Results
In Calu-3 cells, apabetalone dose-dependently downregulated poly I:C induced transcription of key COVID-19 associated cytokines (IL6, CXCL10, CCL2) to a similar extent as baricitinib (up to 86%, p<0.0001), an anti-inflammatory agent in emergency use for COVID-19 treatment. Moreover, apabetalone but not baricitinib diminished IL1B mRNA levels (up to 66%, p<0.0001). Apabetalone and baricitinib opposed poly I:C induced expression of IFNB1 (an IFN-I), IRF1 and IRF9 (upstream regulators) as well as IFIT1 and IFIT2 (downstream ISGs that regulate CXCL10 expression; up to 90%, p<0.0001). Clinically relevant doses of apabetalone did not alter expression of anti-viral IFITM2, an ISG that blocks SARS-CoV-2, particularly omicron, endosomal entry [6]. Therefore, apabetalone counters the expression of inflammatory factors with roles in CS and IFN-I signaling in response to poly I:C. Additionally, apabetalone reduced delta and wild-type spike protein binding to unstimulated Calu-3 cells (up to 72%, p<0.0001).
Conclusions
Apabetalone's dual anti-viral and anti-inflammatory mechanism positions it as a variant-independent COVID-19 therapeutic. Together with an established safety profile from >2000 treatment-years with apabetalone, the data provide rationale for an ongoing clinical trial (NCT04894266) which includes analysis of cardiac damage.
Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): Resverlogix Corp
Collapse
Affiliation(s)
- L Fu
- Resverlogix Corp. , Calgary , Canada
| | - D Gilham
- Resverlogix Corp. , Calgary , Canada
| | - S Stotz
- Resverlogix Corp. , Calgary , Canada
| | - C Sarsons
- Resverlogix Corp. , Calgary , Canada
| | - B Rakai
- Resverlogix Corp. , Calgary , Canada
| | | | - S Wasiak
- Resverlogix Corp. , Calgary , Canada
| | | | - M Sweeney
- Resverlogix Corp. , Calgary , Canada
| | - N Wong
- Resverlogix Corp. , Calgary , Canada
| | | |
Collapse
|
19
|
Siddiqui A, Echols J, Fu L, Keeling K. 637 Messenger ribonucleic acid binding proteins PTBP1 and HNRNPL modulate cystic fibrosis transmembrane conductance regulator messenger ribonucleic acid abundance. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)01327-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
20
|
Meng DF, Ma J, Fu L. 1328P Association of socioeconomic disparities with nasopharyngeal carcinoma survival in an endemic area, China. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1461] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
21
|
Abstract
The concept of traditional Chinese medicine has different connotations and extensions in different historical periods. This paper examines the formation and development of the concept of traditional Chinese medicine in the perspective of history, theory and empirical research, and explores the internal connection among different medical systems and between medicine and other disciplines. It attempts to re-define the connotation and extension of the concept of traditional Chinese medicine in the context of the new era, provide references for building the medical community of the Chinese nation and promote the standardization of Chinese medicine terminology, advance the cross-disciplinary construction and establishing a new medical system with the characteristics of openness and tolerance, in order to provide the solution, wisdom and power of traditional Chinese medicine for global health in the process of building a community of human health.
Collapse
Affiliation(s)
- L Fu
- National Resource Center for Chinese Materia Medica,China Academy of Chinese Medical Science, Beijing, 100700, China Postdoctoral Research Station of China Academy of Chinese Medical Science, Beijing 100700, China
| | - Y R Wang
- The China Institute for History of Medicine and Medical Literature, China Academy of Chinese Medical Science, Beijing 100700, China
| | - Y P Zhao
- China Academy of Chinese Medical Science, Beijing 100700, China
| | - L Q Huang
- China Academy of Chinese Medical Science, Beijing 100700, China
| |
Collapse
|
22
|
Xiong P, Liu T, Huang H, Yuan Y, Zhang W, Fu L, Chen Y. IL-27 overexpression alleviates inflammatory response in allergic asthma by inhibiting Th9 differentiation and regulating Th1/Th2 balance. Immunopharmacol Immunotoxicol 2022; 44:712-718. [PMID: 35695698 DOI: 10.1080/08923973.2022.2077755] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
OBJECTIVE To investigate the effect of IL-27 on Th9 differentiation and Th1/Th2 balance. METHODS C57BL/6 (B6) mice were treated with ovalbumin to establish an allergic asthma (AA) model and subjected to IL-27 overexpression (OV) and empty vector (EV). Hematoxylin-eosin (HE) staining was performed to observe lung tissue inflammation. Flow cytometry was carried out to evaluate the percentage of Th9, Th1, and Th2 cells. The expression of IL-27, IL-27R, IL-9, T-bet, IFN-γ, and IgE was evaluated by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA). Western blot was conducted to observe the expression of pSTAT-1 and pSTAT-3. RESULTS Compared with the Model group, the number of Th1 cells in the Model + OV group increased significantly (p < .05), while those of Th9 and Th2 cells decreased significantly (p < .05). The expression of IL-27, IL-27R, and IFN-γ in blood serum was increased (p < .05), and that of IL-9 and IgE was significantly decreased in the Model + OV group compared to the Model (p < .05). Western blot revealed that Model + OV exhibited lower expression of pSTAT-3 than that in the Model and Model + EV groups (p < .05), while pSTAT-1 expression was significantly increased (p < .05). Inflammatory infiltration in the Model + OV group was significantly reduced, and there was no significant difference between the Model and Model + EV groups. CONCLUSIONS IL-27 OV inhibits Th9 differentiation and regulates the imbalance of Th1/Th2, thereby alleviating inflammatory response in AA. The findings suggest that IL-27 OV may be a potential strategy for clinical treatment of AA.
Collapse
Affiliation(s)
- Peng Xiong
- Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China
| | - Tonglin Liu
- Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China
| | - Hao Huang
- Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China
| | - Yi Yuan
- Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China
| | - Wendi Zhang
- Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China
| | - Lina Fu
- Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China
| | - Yu Chen
- Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China
| |
Collapse
|
23
|
Liu HT, Fu L, Wang B, Wang N, Li DS, Ding YM, Yao R, Qi XT, Lu Y. [Study on the pharmacodynamic activity of combinations with the new anti-tuberculosis drug pyrifazimine in vitro and in vivo in mouse]. Zhonghua Jie He He Hu Xi Za Zhi 2022; 45:560-566. [PMID: 35658380 DOI: 10.3760/cma.j.cn112147-20211008-00697] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Objective: To evaluate two-drug combination interaction between pyrifazimine(TBI-166) and anti-drug-resistant tuberculosis group A drugs Bedaquiline (BDQ), Moxifloxacin (MFX) and the new anti-tuberculosis drug Delamanid (DLM), SQ109, Q203, and PBTZ169 in vitro and in vivo in mouse, so as to provide basis for TBI-166 combination therapy. Methods: This study was performed from September 2020 to July 2021. The chessboard method was used to evaluate the interaction between TBI-166 and BDQ, MFX, DLM, SQ109, and PBTZ169. The time-killing kinetics method was used to evaluate the anti-tuberculosis activity of the two-drug combination with partial synergy. The BALB/c mouse acute infection model was used to evaluate the anti-tuberculosis activity at 4 and 8 weeks in the two-drug combination group (TBI-166+BDQ, TBI-166+SQ109, TBI-166+PBTZ169, TBI-166+Q203) and monotherapy groups (TBI-166, BDQ, SQ109, PBTZ169, Q203). Data analysis was performed using an independent sample t-test. Results: After TBI-166 combined with anti-tuberculosis drugs, MIC was reduced to 6.25% to 25.00% of TBI-166 monotherapy. After TBI-166 combined with BDQ, SQ109 and PBTZ169, the partial inhibitory concentration index (FICI) values were 0.53, 0.75 and 0.75, respectively; the time sterilization experiment showed that the viable population of Mycobacterium tuberculosis treated with two-drug combination of TBI-166 and BDQ, SQ109, PBTZ169 for 14 days decreased at least 3 log10 CFU/ml. In the mouse experiments, it was found that, the amount of viable bacteria in lung tissue of BDQ, SQ109 and PBTZ169 combined with TBI-166 groups was lower than that of the monotherapy group,respectively. The lung tissue culture of mice in the TBI-166+BDQ group was negative after 4 weeks of treatment, and the number of live bacteria in the lungs of the TBI-166+BDQ group was 1.49 log10CFU lower than that of the BDQ monotherapy group(P<0.01). Conclusion: In vitro and in vivo experiments in mice revealed that TBI-166 had synergistic anti-tuberculosis activity after being combined with BDQ, SQ109 and PBTZ169, respectively.
Collapse
Affiliation(s)
- H T Liu
- Beijing Chest Hospital, Capital Medical University, Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China
| | - L Fu
- Beijing Chest Hospital, Capital Medical University, Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China
| | - B Wang
- Beijing Chest Hospital, Capital Medical University, Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China
| | - N Wang
- Beijing Chest Hospital, Capital Medical University, Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China
| | - D S Li
- Beijing Chest Hospital, Capital Medical University, Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China
| | - Y M Ding
- Beijing Chest Hospital, Capital Medical University, Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China
| | - R Yao
- Beijing Chest Hospital, Capital Medical University, Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China
| | - X T Qi
- Beijing Chest Hospital, Capital Medical University, Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China
| | - Y Lu
- Beijing Chest Hospital, Capital Medical University, Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China
| |
Collapse
|
24
|
Zhang S, Wang L, Yang J, Wang J, Fu L, Fu Y. New insights in the chemical profiling of major metabolites in different pigeon pea cultivars using UPLC-QqQ-MS/MS. Food Res Int 2022; 156:111131. [DOI: 10.1016/j.foodres.2022.111131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Revised: 03/10/2022] [Accepted: 03/11/2022] [Indexed: 11/04/2022]
|
25
|
Zhou Q, Xu P, Ding H, Wang Y, Fu L, Wang B, Liu D. Application value of gray-scale ultrasound and shear wave elastography in differential diagnosis of thyroid nodules. Technol Health Care 2022; 30:1043-1054. [PMID: 35342061 DOI: 10.3233/thc-213137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022]
Abstract
BACKGROUND The global prevalence of thyroid cancer has increased significantly in recent years. Ultrasonography is the preferred method for differentiating benign and malignant thyroid nodules preoperatively and is recommended by guidelines. OBJECTIVE To assess the application value of gray-scale ultrasound and shear wave elastography in distinguishing small thyroid nodules. METHODS A retrospective analysis of 228 thyroid nodules, all of which were confirmed by pathology after surgery or FNA from January 2019 to January 2020, was carried out. All nodules were divided into a ⩽ 5 mm group and a > 5 mm group according to their maximum size. We compared the differences in the gray scale and elastography of the nodules between the two groups and the accuracy of different diagnostic methods. RESULTS The accuracies of gray-scale ultrasound and shear wave elastography in the ⩽ 5 mm group were found to be lower than those in the > 5 mm group, and the gray-scale accuracy was slightly higher than that of shear wave elastography in both groups (p< 0.05). The largest AUC (area under the curve) of elastic parameters in the ⩽ 5 mm and > 5 mm groups was found for Emax and Esd, respectively. Based on a combination of these two parameters, the accuracies of the two groups were significantly higher than those of the parameters or gray scale alone (p< 0.05) and were 84.62% and 85.48%, respectively. CONCLUSION Shear wave elastography is valuable in the diagnosis of benign and malignant thyroid nodules using ultrasonography. When combining gray-scale ultrasound and shear wave elastography, the diagnostic accuracy is obviously improved, especially for ⩽ 5 mm small thyroid nodules.
Collapse
|
26
|
Fu L, Tang X. [Attention should be paid to accurate pathological diagnosis of breast cancer]. Zhonghua Yi Xue Za Zhi 2022; 102:687-689. [PMID: 35280015 DOI: 10.3760/cma.j.cn112137-20211206-02716] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Breast cancer has replaced lung cancer as the most common malignant tumor in the world. Precise surgical, internal medicine, targeted, radiotherapy, immunotherapy and other treatment methods will improve the survival and quality of life of patients. Accurate pathological diagnosis is the prerequisite and key to achieve clinical accurate treatment. This article makes a review of the relevant content of different submitted specimens and precise pathological diagnosis of breast cancer.
Collapse
Affiliation(s)
- L Fu
- Department of Breast Cancer Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
| | - Xiaoyan Tang
- Division of Oncologic Pathology, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo 137-8610, Japan
| |
Collapse
|
27
|
Fu WH, Chen PL, Xia JL, Fu L, Shen Y, He WJ, Chen YH, Ren N, Jiang Q, Ma R, Wang T, Wang XN, Zhang NF, Liu CL. [Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis]. Zhonghua Jie He He Hu Xi Za Zhi 2022; 45:158-170. [PMID: 35135085 DOI: 10.3760/cma.j.cn112147-20210707-00473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Objective: To examine the efficacy and safety of endothelin receptor antagonists (ERA) combined with phosphodiesterase 5 inhibitors (PDE5i) in the treatment of pulmonary artery hypertension (PAH). Methods: Computer-based retrieval was performed on PubMed, Cochrane Library, CNKI, Wanfang, and VIP database (up to February 12th, 2021). Randomized controlled trials about endothelin receptor antagonists (ERAs) or PDE5i in patients with PAH were collected. The change of 6-minute walking distance (6MWD) in 12-16 weeks was used as primary outcome index. Case fatality rate, worsening clinical events, WHO functional class (FC) improvement, adverse events (AEs), serious adverse events (SAE) were the key secondary outcomes indicators. STATA 16.0 software was used for network meta-analysis, and the pooled estimates of odds ratios (ORs) or weighted mean differences (WMDs) and 95% confidence intervals (CIs) of the results were shown. To help explain ORs and WMDs, we used the surface under the cumulative ranking curve (SUCRA) to calculate the probability of each intervention. Results: We included 29 trials with 5 949 participants. In network meta-analysis, Bosentan combined with Sildenafil (WMD=53.93, 95%CI=6.19-101.66) had shown the greatest improvement in 6MWD compared with placebo, followed by Bosentan combined with Tadalafil (WMD=50.84, 95%CI=7.05-94.62), Ambrisentan combined with Tadalafil (WMD=46.67, 95%CI=15.88-77.45), Bosentan (WMD=29.44, 95%CI=5.86-53.02), Ambrisentan (WMD=23.90, 95%CI=0.31-47.48) and Macitentan (WMD=21.57, 95%CI=2.45-40.69). According to SUCRA, the effects of different intervention measures on improving 6MWD in patients with arterial pulmonary hypertension were as follows: Bosentan+Sildenafil (82.9%)>Bosentan+Tadalafil (78.4%)>Ambrisentan+Tadalafil (77.1%)>Bosentan (49.2%)>Sildenafil (48.5%)>Ambrisentan (40.3%)>Macitentan (37.3%)>Tadalafil (33.0%)>Placebo (3.3%). For the WHO functional class, Sildenafil (OR=2.90, 95%CI=1.04-8.08) was optimal compared with placebo, followed by Bosentan (OR=2.15, 95%CI=1.15-4.04), and there was no significant difference in the rest. For clinical worsening, Bosentan combined with Tadalafil (OR=0.08, 95%CI=0.01-0.49) performed best compared with placebo, followed by Bosentan (OR=0.20, 95%CI=0.11-0.38), Bosentan combined with Sildenafil (OR=0.21, 95%CI=0.09-0.46), Ambrisentan combined with Tadalafil (OR=0.27, 95%CI=0.15-0.50), Sildenafil (OR=0.33, 95%CI=0.17-0.66) and Tadalafil (OR=0.44, 95%CI=0.21-0.90). There was no statistical difference between all interventions and placebo in terms of the incidence of adverse events and serious adverse events. For case fatality rate, Ambrisentan (OR=0.28, 95%CI=0.11-0.74) was statistically superior to placebo and there was no statistics difference in the rest. Conclusions: The combination therapy of ERAs and PDE5i performed well in the short-term improvement of motor function. Furthermore, there was no significant difference with monotherapy in terms of safety. However, it is worth emphasizing that the choice of treatment should be based on the patient's individualized situation and the patient's requirements.
Collapse
Affiliation(s)
- W H Fu
- The First Affiliated Hospital of Guangzhou Medical University, National Centre for Respiratory Medicine, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou 510005, China
| | - P L Chen
- The First Affiliated Hospital of Guangzhou Medical University, National Centre for Respiratory Medicine, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou 510005, China
| | - J L Xia
- The First Affiliated Hospital of Guangzhou Medical University, National Centre for Respiratory Medicine, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou 510005, China
| | - L Fu
- The First Affiliated Hospital of Guangzhou Medical University, National Centre for Respiratory Medicine, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou 510005, China
| | - Y Shen
- The First Affiliated Hospital of Guangzhou Medical University, National Centre for Respiratory Medicine, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou 510005, China
| | - W J He
- The First Affiliated Hospital of Guangzhou Medical University, National Centre for Respiratory Medicine, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou 510005, China
| | - Y H Chen
- The First Affiliated Hospital of Guangzhou Medical University, National Centre for Respiratory Medicine, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou 510005, China
| | - N Ren
- The First Affiliated Hospital of Guangzhou Medical University, National Centre for Respiratory Medicine, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou 510005, China
| | - Q Jiang
- The First Affiliated Hospital of Guangzhou Medical University, National Centre for Respiratory Medicine, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou 510005, China
| | - R Ma
- The First Affiliated Hospital of Guangzhou Medical University, National Centre for Respiratory Medicine, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou 510005, China
| | - T Wang
- The First Affiliated Hospital of Guangzhou Medical University, National Centre for Respiratory Medicine, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou 510005, China
| | - X N Wang
- The First Affiliated Hospital of Guangzhou Medical University, National Centre for Respiratory Medicine, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou 510005, China
| | - N F Zhang
- The First Affiliated Hospital of Guangzhou Medical University, National Centre for Respiratory Medicine, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou 510005, China
| | - C L Liu
- The First Affiliated Hospital of Guangzhou Medical University, National Centre for Respiratory Medicine, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou 510005, China
| |
Collapse
|
28
|
Fan Z, Wu Y, Zhao L, Fu L, Deng L, Deng J, Ding D, Xiao S, Deng X, Peng S, Pan Z. MYB308-mediated transcriptional activation of plasma membrane H + -ATPase 6 promotes iron uptake in citrus. Hortic Res 2022; 9:uhac088. [PMID: 35685222 PMCID: PMC9171118 DOI: 10.1093/hr/uhac088] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/29/2021] [Accepted: 03/30/2022] [Indexed: 05/15/2023]
Abstract
Iron-deficiency chlorosis is a common nutritional disorder in crops grown on alkaline or calcareous soils. Although the acclimation mechanism to iron deficiency has been investigated, the genetic regulation of iron acquisition is still unclear. Here, by comparing the iron uptake process between the iron-poor-soil-tolerant citrus species Zhique (ZQ) and the iron-poor-soil-sensitive citrus species trifoliate orange (TO), we discovered that enhanced root H + efflux is crucial for the tolerance to iron deficiency in ZQ. The H+ efflux is mainly regulated by a plasma membrane-localized H+-ATPase, HA6, the expression of which is upregulated in plants grown in soil with low iron content, and significantly higher in the roots of ZQ than TO. Overexpression of the HA6 gene in the Arabidopsis thaliana aha2 mutant, defective in iron uptake, recovered the wild-type phenotype. In parallel, overexpression of the HA6 gene in TO significantly increased iron content of plants. Moreover, an iron deficiency-induced transcription factor, MYB308, was revealed to bind the promoter and activate the expression of HA6 in ZQ in yeast one-hybrid, electrophoretic mobility shift, and dual-luciferase assays. Overexpression of MYB308 in ZQ roots significantly increased the expression level of the HA6 gene. However, MYB308 cannot bind or activate the HA6 promoter in TO due to the sequence variation of the corresponding MYB308 binding motif. Taking these results together, we propose that the MYB308 could activate HA6 to promote root H+ efflux and iron uptake, and that the distinctive MYB308-HA6 transcriptional module may be, at least in part, responsible for the iron deficiency tolerance in citrus.
Collapse
Affiliation(s)
- Zhengyan Fan
- Key Laboratory of Horticultural Plant Biology (Ministry of Education), Key Laboratory of Horticultural Crop Biology and Genetic Improvement (Central Region, Ministry of Agriculture), College of Horticulture and Forestry Sciences, Huazhong Agricultural University, Wuhan 430070, China
| | - Yifang Wu
- Key Laboratory of Horticultural Plant Biology (Ministry of Education), Key Laboratory of Horticultural Crop Biology and Genetic Improvement (Central Region, Ministry of Agriculture), College of Horticulture and Forestry Sciences, Huazhong Agricultural University, Wuhan 430070, China
| | - Liuying Zhao
- Key Laboratory of Horticultural Plant Biology (Ministry of Education), Key Laboratory of Horticultural Crop Biology and Genetic Improvement (Central Region, Ministry of Agriculture), College of Horticulture and Forestry Sciences, Huazhong Agricultural University, Wuhan 430070, China
| | - Lina Fu
- Key Laboratory of Horticultural Plant Biology (Ministry of Education), Key Laboratory of Horticultural Crop Biology and Genetic Improvement (Central Region, Ministry of Agriculture), College of Horticulture and Forestry Sciences, Huazhong Agricultural University, Wuhan 430070, China
| | - Lile Deng
- Key Laboratory of Horticultural Plant Biology (Ministry of Education), Key Laboratory of Horticultural Crop Biology and Genetic Improvement (Central Region, Ministry of Agriculture), College of Horticulture and Forestry Sciences, Huazhong Agricultural University, Wuhan 430070, China
| | - Jiarui Deng
- Chenggu Fruit Industry Technical Guidance Station, Shaanxi 723200, China
| | - Dekuan Ding
- Chenggu Fruit Industry Technical Guidance Station, Shaanxi 723200, China
| | - Shunyuan Xiao
- Institute for Bioscience and Biotechnology Research & Department of Plant Sciences and Landscape Architecture, University of Maryland College Park, Rockville, MD 20850, USA
| | - Xiuxin Deng
- Key Laboratory of Horticultural Plant Biology (Ministry of Education), Key Laboratory of Horticultural Crop Biology and Genetic Improvement (Central Region, Ministry of Agriculture), College of Horticulture and Forestry Sciences, Huazhong Agricultural University, Wuhan 430070, China
| | - Shu’ang Peng
- Key Laboratory of Horticultural Plant Biology (Ministry of Education), Key Laboratory of Horticultural Crop Biology and Genetic Improvement (Central Region, Ministry of Agriculture), College of Horticulture and Forestry Sciences, Huazhong Agricultural University, Wuhan 430070, China
| | | |
Collapse
|
29
|
Wu S, Guo S, Fu L, Du C, Luo X. Case Report: Glycogen Storage Disease Type Ia in a Chinese Child Treated With Growth Hormone. Front Pediatr 2022; 10:921323. [PMID: 35783312 PMCID: PMC9249018 DOI: 10.3389/fped.2022.921323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/15/2022] [Accepted: 05/31/2022] [Indexed: 12/05/2022] Open
Abstract
BACKGROUND Glycogen storage disease type Ia is a rare metabolic disorder that leads to excessive glycogen and fat accumulation in organs, characterized by hepatomegaly, hypoglycemia, lactic acidemia, hyperlipidemia, hyperuricemia, puberty delay, and growth retardation. Here, we report on a patient with glycogen storage disease type Ia treated with growth hormone. CASE PRESENTATION A 10-year-old boy had growth retardation for 6 years, and was admitted to clarify the cause of his short stature. We found that his bone age was 5.5 years, significantly lower than his physical age, while his serum IGF-1 and IGFBP-3 were 23.30 and 1620.0 ng/mL, respectively, both lower than normal. His medical history revealed that he had suffered from steatohepatitis, hyperlipidemia, and hypoglycemia since he was 11 months of age. Whole exome sequencing (WES) showed compound heterozygous mutations in exons 2 and 5 of the glucose-6-phosphatase (G6PC) gene on chromosome 17: c.G248A (p.R83H) and c.G648T (p.L216L). The patient was finally diagnosed with GSD Ia. After growth hormone (GH) treatment and corn starch therapy for 14 months, his height significantly increased (by 13 cm). The serum IGF-1 level increased to the normal range but his lipid levels and liver function did not significantly increase. CONCLUSION We describe a young patient with a compound heterozygous G6PC variant in a Chinese family; his height increased significantly after growth hormone and corn starch interventions. This case emphasizes that WES is essential for early diagnosis, and that growth hormone treatment may increase the height of patients with GSD Ia safely.
Collapse
Affiliation(s)
- Shimin Wu
- Department of Pediatrics, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China
| | - Shusen Guo
- Department of Pediatrics, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China
| | - Lina Fu
- Department of Pediatrics, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China
| | - Caiqi Du
- Department of Pediatrics, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China
| | - Xiaoping Luo
- Department of Pediatrics, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China
| |
Collapse
|
30
|
Bedwell D, Sharma J, Du M, Wong E, Mutyam V, Li Y, Chen J, Wangen J, Thrasher K, Fu L, Peng N, Tang L, Liu K, Mathew B, Bostwick B, Augelli-Szafran C, Bihler H, Liang F, Mahiou J, Saltz J, Rab A, Hong J, Sorscher E, Mendenhall E, Coppola C, Keeling K, Green R, Mense M, Suto M, Rowe S. 531: Identification of a compound that mediates readthrough of CFTR nonsense mutations by reducing eRF1 levels. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)01955-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
31
|
Lilley CM, Marin MJ, Wiencek J, Fu L, Wolniak K, Kanakis CE, Hermelin D, Scordino T, Thomas C, Mirza KM, Demas C. The Utility of PathElective.com as a Curricular Adjunct in Laboratory Medicine Education. Am J Clin Pathol 2021. [PMCID: PMC8574499 DOI: 10.1093/ajcp/aqab191.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
Introduction/Objective PathElective.com was founded as a means of combating stagnating resident and medical student education due to halting of in-person educational activities during the COVID-19 pandemic. The site has since grown to be included in medical student and resident training programs at numerous institutions across the world, serving as a unique means of delivering high-quality and trackable laboratory medicine education. Methods/Case Report The PathElective website was developed using Squarespace, video lectures were recorded by each professor or sourced from openly available web resources incorporating virtual slides, reading assignments, or relevant podcasts at the course director’s discretion. Monthly website traffic data were obtained through Squarespace analytics for the first 11 months of the website being available (May 1, 2020, to April 22, 2021). Geographic and source data were obtained through deidentified IP address analysis built-in to Squarespace analytics. Students who registered to take the online courses were assessed before and after interacting with the course materials using a dual form crossover quiz design to prevent memorization of questions and assess comprehension. Quiz data were all anonymous and improvement was determined using a paired t-test. Comparisons between courses were made via percentage improvements. Results (if a Case Study enter NA) Over the tracking period, PathElective.com received 352,012 page views, 73,550 visits, 33,225 unique visitors, and accrued 5,815 registered users. Most of the visitors (72.8%) arrived at the site via a direct URL input, 14.9% through a search engine, and 10.6% through social media. Most visitors were from the US (43.8%) or India (11.9%). With a total of 1598 test pairs being analyzed from all clinical pathology modules, the average increase in score was 14.4% (95%, CI=10.3-18.6, p=0.0052). All courses experienced a statistically significant increase in scores except for Clinical Chemistry lesson 3.2 (7%, -1.8-15.9% CI, p=0.12). Courses were well received with a median satisfaction score was very satisfied in all six assessment categories. Conclusion PathElective.com is a free and effective means of enhancing clinical pathology training in medical education. Students liked the online format, the quality of the lectures, and course faculty, and felt they could get help if needed. An area of improvement for this platform would be the interaction with students on social media.
Collapse
Affiliation(s)
- C M Lilley
- Stritch School of Medicine, Loyola University Chicago, Chicago, Illinois, UNITED STATES
| | - M J Marin
- Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, Florida, UNITED STATES
| | - J Wiencek
- Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, UNITED STATES
| | - L Fu
- Stritch School of Medicine, Loyola University Chicago, Chicago, Illinois, UNITED STATES
| | - K Wolniak
- Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, UNITED STATES
| | - C E Kanakis
- Department of Pathology and Laboratory Medicine, Loyola University Medical Center, Maywood, Illinois, UNITED STATES
| | - D Hermelin
- Department of Pathology, Anatomic & Clinical, Saint Louis University School of Medicine, St. Louis, Missouri, UNITED STATES
| | - T Scordino
- Department of Pathology, University of Oklahoma Medical Center, Oklahoma City, Oklahoma, UNITED STATES
| | - C Thomas
- Department of Pathology, University of Oklahoma Medical Center, Oklahoma City, Oklahoma, UNITED STATES
| | - K M Mirza
- Department of Pathology and Laboratory Medicine, Loyola University Medical Center, Maywood, Illinois, UNITED STATES
| | - C Demas
- Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, UNITED STATES
| |
Collapse
|
32
|
Gilham D, Smith AL, Fu L, Moore DY, Muralidharan A, Reid SPM, Stotz SC, Johansson JO, Sweeney M, Wong NCW, El-Gamal D, Kulikowski E. Bromodomain and extraterminal (BET) protein inhibitor, apabetalone, reduces ACE2 expression and attenuates SARS-CoV-2 infection in vitro. Eur Heart J 2021. [PMCID: PMC8767620 DOI: 10.1093/eurheartj/ehab724.3267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Background/Introduction SARS-CoV-2 causes life threatening COVID-19 complications including acute coronary syndrome, venous thromboembolism, hyperinflammation and damage in multiple tissues. The SARS-CoV-2 “spike protein” binds cell surface receptors including angiotensin-converting enzyme 2 (ACE2) for entry into host cells to initiate infection. Host cell dipeptidyl peptidase-4 (DPP4 / CD26) is implicated as a cofactor in uptake. Recent evidence indicates expression of factors involved in SARS-CoV-2 uptake into host cells is regulated by BET proteins, epigenetic readers modulating gene expression. Apabetalone, the most clinically advanced BET inhibitor (BETi), is in phase 3 trials for cardiovascular disease (CVD) (a,b). In cultured human cardiomyocytes, apabetalone suppressed infection with SARS-CoV-2 and prevented dysfunction of cardiac organoids induced by the cytokine-storm that arises in patients with severe symptoms (c). However, anti-viral properties of apabetalone in other cell types are not known. Purpose To examine effects of apabetalone on SARS-CoV-2 infection in cell culture via downregulated expression of cell surface receptors involved in viral entry. Cell systems used mimic initial sites of infection in the lung as well as cell types contributing to complications in late stages of infection. Methods Gene expression was measured by real-time PCR, protein levels by immunoblot or flow cytometry, and binding of recombinant SARS-CoV-2 spike protein by flow cytometry. Infection with SARS-CoV-2 was determined in a BSL3 facility. Infectivity was quantified by determining levels of viral spike protein amongst total cells via imaging on an Operetta CLS. Results In Calu-3, a human bronchial epithelial cell line, apabetalone dose-dependently downregulated ACE2 gene expression (up to 98%), reduced ACE2 protein levels (up to 84%) and diminished binding of SARS-CoV-2 spike protein (up to 77%, p<0.001 for all parameters). Further, apabetalone abolished infection of Calu-3 cells with live SARS-CoV-2, which was comparable to other antiviral agents. Apabetalone-driven ACE2 downregulation was also observed in extrapulmonary cell types including HepG2, Huh-7 or primary hepatocytes (up to 90%, p<0.001 for all cell types), and Vero E6, a monkey kidney epithelial cell line (up to 38%, p<0.05). DPP4/CD26, a potential cofactor for SARS-CoV-2 uptake, was also downregulated by apabetalone in Calu-3 cells (mRNA ∼65% and protein ∼40%, p<0.001), which may be synergistic with ACE2 reductions to impede SARS-CoV-2 infection. Conclusions Apabetalone, an investigational drug for CVD, reduced cell surface receptors (ACE2 and DPP4) involved in SARS-CoV-2 uptake into host cells and dramatically attenuated SARS-CoV-2 infection/propagation in vitro. Our results suggest apabetalone can mitigate SARS-CoV-2 replication in multiple organs, which together with an established safety profile supports clinical evaluation of apabetalone to treat Funding Acknowledgement Type of funding sources: Public Institution(s). Main funding source(s): COVID-19 Rapid Response Grant from the College of Medicine at the University of Nebraska Medical Center (to DE and SPMR), and by University of Nebraska Medical Center start-up funds (to DE).
Graphical Abstract ![]()
Collapse
Affiliation(s)
- D Gilham
- Resverlogix Corp., Calgary, Canada
| | - A L Smith
- University of Nebraska Medical Center, Eppley Institute for Research in Cancer and Allied Diseases, Omaha, United States of America
| | - L Fu
- Resverlogix Corp., Calgary, Canada
| | - D Y Moore
- University of Nebraska Medical Center, Eppley Institute for Research in Cancer and Allied Diseases, Omaha, United States of America
| | - A Muralidharan
- University of Nebraska Medical Center, Department of Pathology and Microbiology, Omaha, United States of America
| | - S P M Reid
- University of Nebraska Medical Center, Department of Pathology and Microbiology, Omaha, United States of America
| | | | - J O Johansson
- Resverlogix Inc., San Francisco, United States of America
| | - M Sweeney
- Resverlogix Inc., San Francisco, United States of America
| | | | - D El-Gamal
- University of Nebraska Medical Center, Eppley Institute for Research in Cancer and Allied Diseases, Omaha, United States of America
| | | |
Collapse
|
33
|
Hu SS, Fu L, Han SY, Li XL, Zhang LD. LINC01605 regulates proliferation, migration and invasion of colorectal cancer cells via targeting miR-3960/SOX11. Eur Rev Med Pharmacol Sci 2021; 25:1322-1329. [PMID: 33629302 DOI: 10.26355/eurrev_202102_24837] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE We aimed to determine the expression level of long intergenic non-coding ribonucleic acid 1605 (LINC01605) in colorectal cancer (CRC), and to explore the effects of the LINC01605/microRNA (miR)-3960/sex-determining region Y-box 11 (SOX11) regulatory axis on the biological behaviors of CRC cells and the molecular mechanism therein. PATIENTS AND METHODS Tissue specimens were collected from 38 patients with CRC, and the relative expression level of LINC01605 in the CRC tissues and CRC cells was measured using quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Then, the effects of LINC01605 on the proliferation, apoptosis, invasion and metastasis of CRC cells were observed via in vitro assays [cell counting kit (CCK)-8 assay, flow cytometry and transwell assay]. Besides, the possible miRNAs binding to LINC01605 were predicted by the bioinformatics method, and they were screened and verified using qRT-PCR and Dual-Luciferase reporter gene assay. Finally, the downstream target genes of miR-3960 were predicted by means of bioinformatics, and they were also screened and confirmed via qRT-PCR and Dual-Luciferase reporter gene assay. RESULTS According to the results of qRT-PCR, the expression of LINC01605 was up-regulated in 31 out of 38 cases of CRC tissue specimens, and its expression in CRC cells was higher than that in normal colorectal cells. The results of in vitro assays revealed that the proliferation, migration and invasion abilities of CRC cells were weakened, with an increased apoptosis rate after interference with LINC01605 expression. Based on the results of qRT-PCR and Dual-Luciferase reporter gene assay, miR-3960 was the target of LINC01605, while SOX11 was the target of miR-3960. Moreover, the expression of miR-3960 rose, but that of SOX11 declined after interference with LINC01605 expression. It was found through Western blotting that the protein expression of SOX11 was lowered after interference with LINC01605 expression. CONCLUSIONS LINC01605 has an up-regulated expression in CRC, and accelerates the proliferation, migration and metastasis of CRC cells by the miR-3960/SOX11 regulatory axis.
Collapse
Affiliation(s)
- S-S Hu
- Department of Gastroenterology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, China.
| | | | | | | | | |
Collapse
|
34
|
Fu L, Li J, Wang G, Luan Y, Dai W. Adsorption behavior of organic pollutants on microplastics. Ecotoxicol Environ Saf 2021; 217:112207. [PMID: 33866287 DOI: 10.1016/j.ecoenv.2021.112207] [Citation(s) in RCA: 202] [Impact Index Per Article: 67.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/13/2020] [Revised: 02/26/2021] [Accepted: 03/28/2021] [Indexed: 05/19/2023]
Abstract
Microplastics (MPs) are emerging pollutants that act as a carrier of toxic pollutants, release toxic substances, and aggregate in biota. The adsorption behavior of MPs has recently become a research hot spot. The objective of this study was to summarize the main mechanisms by which MPs adsorb organic pollutants, introduce some mathematical models commonly used to study the adsorption behavior of MPs, and discuss the factors affecting the adsorption capacity from three perspectives, i.e., the properties of MPs and organic pollutants, and environmental factors. Adsorption kinetics and isothermal adsorption models are commonly used to study the adsorption of organic pollutants on MPs. We observed that hydrophobic interaction is the most common mechanism by which MPs adsorb organic pollutants, and also reportedly controls the portion of organic pollutants. Additionally, electrostatic interaction and other non-covalent forces, such as hydrogen bonds, halogen bonds, and π-π interactions, are also mechanisms of organic pollutant adsorption on MPs. The particle size, specific surface area, aging degree, crystallinity, and polarity of MPs, and organic pollutant properties (hydrophobicity and dissociated forms) are key factors affecting adsorption capacity. Changes in the pH, temperature, and ionic strength also affect the adsorption capacity. Current research on the adsorption behavior of MPs has mainly been conducted in laboratories, and in-depth studies on the adsorption mechanism and influencing factors are limited. Therefore, studies on the adsorption behavior of MPs in the environment are required, and this study will contribute to a better understanding of this topic.
Collapse
Affiliation(s)
- Lina Fu
- College of Forestry, Beijing Forestry University, Beijing 100083, China
| | - Jing Li
- College of Forestry, Beijing Forestry University, Beijing 100083, China
| | - Guoyu Wang
- China Urban Construction Design & Research Institute CO. LTD., Beijing 100120, China
| | - Yaning Luan
- College of Forestry, Beijing Forestry University, Beijing 100083, China.
| | - Wei Dai
- College of Forestry, Beijing Forestry University, Beijing 100083, China.
| |
Collapse
|
35
|
Li YW, Zheng HJ, Fang YQ, Zhang DQ, Chen YJ, Chen C, Liang AJ, Shi WJ, Pei D, Xu LX, Liu S, Pan J, Lu DH, Hashimoto M, Barinov A, Jung SW, Cacho C, Wang MX, He Y, Fu L, Zhang HJ, Huang FQ, Yang LX, Liu ZK, Chen YL. Observation of topological superconductivity in a stoichiometric transition metal dichalcogenide 2M-WS 2. Nat Commun 2021; 12:2874. [PMID: 34001892 PMCID: PMC8129086 DOI: 10.1038/s41467-021-23076-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2021] [Accepted: 04/11/2021] [Indexed: 02/03/2023] Open
Abstract
Topological superconductors (TSCs) are unconventional superconductors with bulk superconducting gap and in-gap Majorana states on the boundary that may be used as topological qubits for quantum computation. Despite their importance in both fundamental research and applications, natural TSCs are very rare. Here, combining state of the art synchrotron and laser-based angle-resolved photoemission spectroscopy, we investigated a stoichiometric transition metal dichalcogenide (TMD), 2M-WS2 with a superconducting transition temperature of 8.8 K (the highest among all TMDs in the natural form up to date) and observed distinctive topological surface states (TSSs). Furthermore, in the superconducting state, we found that the TSSs acquired a nodeless superconducting gap with similar magnitude as that of the bulk states. These discoveries not only evidence 2M-WS2 as an intrinsic TSC without the need of sensitive composition tuning or sophisticated heterostructures fabrication, but also provide an ideal platform for device applications thanks to its van der Waals layered structure.
Collapse
Affiliation(s)
- Y. W. Li
- grid.440637.20000 0004 4657 8879School of Physical Science and Technology, ShanghaiTech University, Shanghai, 201210 People’s Republic of China ,grid.4991.50000 0004 1936 8948Department of Physics, University of Oxford, Oxford, OX1 3PU UK ,ShanghaiTech Laboratory for Topological Physics, Shanghai, 201210 People’s Republic of China
| | - H. J. Zheng
- grid.440637.20000 0004 4657 8879School of Physical Science and Technology, ShanghaiTech University, Shanghai, 201210 People’s Republic of China ,ShanghaiTech Laboratory for Topological Physics, Shanghai, 201210 People’s Republic of China ,grid.410726.60000 0004 1797 8419University of Chinese Academy of Sciences, Beijing, 100049 People’s Republic of China
| | - Y. Q. Fang
- grid.454856.e0000 0001 1957 6294State Key Laboratory of High Performance Ceramics and Superfine Microstructure Shanghai Institute of Ceramics Chinese Academy of Science, Shanghai, 200050 People’s Republic of China ,grid.11135.370000 0001 2256 9319State Key Laboratory of Rare Earth Materials Chemistry and Applications College of Chemistry and Molecular Engineering, Peking University, Beijing, 100871 People’s Republic of China
| | - D. Q. Zhang
- grid.411485.d0000 0004 1755 1108School of Physics, China Jiliang University, Hangzhou, 310018 People’s Republic of China ,grid.41156.370000 0001 2314 964XNational Laboratory of Solid State Microstructures and School of Physics Nanjing University, Nanjing, 210093 People’s Republic of China ,grid.509497.6Collaborative Innovation Center of Advanced Microstructures, Nanjing, 210093 People’s Republic of China
| | - Y. J. Chen
- grid.12527.330000 0001 0662 3178State Key Laboratory of Low Dimensional Quantum Physics, Department of Physics, Tsinghua University, Beijing, 100084 People’s Republic of China
| | - C. Chen
- grid.440637.20000 0004 4657 8879School of Physical Science and Technology, ShanghaiTech University, Shanghai, 201210 People’s Republic of China ,ShanghaiTech Laboratory for Topological Physics, Shanghai, 201210 People’s Republic of China ,grid.184769.50000 0001 2231 4551Advanced Light Source, Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - A. J. Liang
- grid.440637.20000 0004 4657 8879School of Physical Science and Technology, ShanghaiTech University, Shanghai, 201210 People’s Republic of China ,ShanghaiTech Laboratory for Topological Physics, Shanghai, 201210 People’s Republic of China
| | - W. J. Shi
- grid.440637.20000 0004 4657 8879Center for Transformative Science, ShanghaiTech University, Shanghai, 201210 People’s Republic of China ,grid.440637.20000 0004 4657 8879Shanghai high repetition rate XFEL and extreme light facility (SHINE), ShanghaiTech University, Shanghai, 201210 People’s Republic of China
| | - D. Pei
- grid.4991.50000 0004 1936 8948Department of Physics, University of Oxford, Oxford, OX1 3PU UK
| | - L. X. Xu
- grid.440637.20000 0004 4657 8879School of Physical Science and Technology, ShanghaiTech University, Shanghai, 201210 People’s Republic of China ,grid.410726.60000 0004 1797 8419University of Chinese Academy of Sciences, Beijing, 100049 People’s Republic of China
| | - S. Liu
- grid.440637.20000 0004 4657 8879School of Physical Science and Technology, ShanghaiTech University, Shanghai, 201210 People’s Republic of China ,grid.410726.60000 0004 1797 8419University of Chinese Academy of Sciences, Beijing, 100049 People’s Republic of China
| | - J. Pan
- grid.454856.e0000 0001 1957 6294State Key Laboratory of High Performance Ceramics and Superfine Microstructure Shanghai Institute of Ceramics Chinese Academy of Science, Shanghai, 200050 People’s Republic of China
| | - D. H. Lu
- grid.445003.60000 0001 0725 7771Stanford Synchrotron Radiation Lightsource, SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - M. Hashimoto
- grid.445003.60000 0001 0725 7771Stanford Synchrotron Radiation Lightsource, SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - A. Barinov
- grid.5942.a0000 0004 1759 508XElettra-Sincrotrone Trieste, Trieste, Basovizza, 34149 Italy
| | - S. W. Jung
- grid.18785.330000 0004 1764 0696Diamond Light Source, Harwell Campus, Didcot, OX11 0DE UK ,grid.256681.e0000 0001 0661 1492Department of Physics, Gyeongsang National University, Jinju, 52828 Korea
| | - C. Cacho
- grid.18785.330000 0004 1764 0696Diamond Light Source, Harwell Campus, Didcot, OX11 0DE UK
| | - M. X. Wang
- grid.440637.20000 0004 4657 8879School of Physical Science and Technology, ShanghaiTech University, Shanghai, 201210 People’s Republic of China ,ShanghaiTech Laboratory for Topological Physics, Shanghai, 201210 People’s Republic of China
| | - Y. He
- grid.47840.3f0000 0001 2181 7878Department of Physics, University of California at Berkeley, Berkeley, CA 94720 USA
| | - L. Fu
- grid.116068.80000 0001 2341 2786Department of Physics, Massachusetts Institute of Technology, Cambridge, MA 02139 USA
| | - H. J. Zhang
- grid.41156.370000 0001 2314 964XNational Laboratory of Solid State Microstructures and School of Physics Nanjing University, Nanjing, 210093 People’s Republic of China ,grid.509497.6Collaborative Innovation Center of Advanced Microstructures, Nanjing, 210093 People’s Republic of China
| | - F. Q. Huang
- grid.454856.e0000 0001 1957 6294State Key Laboratory of High Performance Ceramics and Superfine Microstructure Shanghai Institute of Ceramics Chinese Academy of Science, Shanghai, 200050 People’s Republic of China ,grid.11135.370000 0001 2256 9319State Key Laboratory of Rare Earth Materials Chemistry and Applications College of Chemistry and Molecular Engineering, Peking University, Beijing, 100871 People’s Republic of China
| | - L. X. Yang
- grid.12527.330000 0001 0662 3178State Key Laboratory of Low Dimensional Quantum Physics, Department of Physics, Tsinghua University, Beijing, 100084 People’s Republic of China ,Frontier Science Center for Quantum Information, Beijing, 100084 People’s Republic of China
| | - Z. K. Liu
- grid.440637.20000 0004 4657 8879School of Physical Science and Technology, ShanghaiTech University, Shanghai, 201210 People’s Republic of China ,ShanghaiTech Laboratory for Topological Physics, Shanghai, 201210 People’s Republic of China
| | - Y. L. Chen
- grid.440637.20000 0004 4657 8879School of Physical Science and Technology, ShanghaiTech University, Shanghai, 201210 People’s Republic of China ,grid.4991.50000 0004 1936 8948Department of Physics, University of Oxford, Oxford, OX1 3PU UK ,ShanghaiTech Laboratory for Topological Physics, Shanghai, 201210 People’s Republic of China ,grid.12527.330000 0001 0662 3178State Key Laboratory of Low Dimensional Quantum Physics, Department of Physics, Tsinghua University, Beijing, 100084 People’s Republic of China
| |
Collapse
|
36
|
Bao Y, Yang N, Meng J, Wang D, Fu L, Wang J, Cang J. Adaptability of winter wheat Dongnongdongmai 1 (Triticum aestivum L.) to overwintering in alpine regions. Plant Biol (Stuttg) 2021; 23:445-455. [PMID: 33075203 DOI: 10.1111/plb.13200] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/31/2020] [Accepted: 10/09/2020] [Indexed: 06/11/2023]
Abstract
Long winters led to a one-crop-a-year cultivation system until the winter wheat Dongnongdongmai 1 (Dn1) was successfully cultivated in northeast China. This crop variety is resistant to extremely low temperatures (-35 °C). To better understand the adaptability of winter wheat Dn1 to low temperatures, gas chromatography time-of-flight mass spectrometry (GC-TOF/MS) and metabolomics analysis was conducted on the tillering nodes of winter wheat during the overwintering period. Enzyme-regulating genes of the metabolic products were also quantitatively analysed. The metabolomic results for the tillering nodes in the overwintering period showed that disaccharides had a strong protective effect on winter wheat Dn1. Amino acid metabolism (i.e. proline, alanine and GABA) changed significantly throughout the whole wintering process, whereas organic fatty acid metabolism changed significantly only in the late stage of overwintering. This result indicates that the metabolites used by winter wheat Dn1 differ in different overwintering stages. The relationship between field temperature and metabolite changes in winter wheat Dn1 during overwintering periods is discussed, and disaccharides were identified as the osmotic stress regulators for winter wheat Dn1 during the overwintering process, as well as maintenance of the carbon and nitrogen balance by monosaccharides, amino acids and lipids for cold resistance.
Collapse
Affiliation(s)
- Y Bao
- College of Life Science, Northeast Agricultural University, Harbin, China
| | - N Yang
- College of Life Science, Northeast Agricultural University, Harbin, China
| | - J Meng
- College of Life Science, Northeast Agricultural University, Harbin, China
| | - D Wang
- College of Life Science, Northeast Agricultural University, Harbin, China
| | - L Fu
- College of Agriculture, Northeast Agricultural University, Harbin, China
| | - J Wang
- College of Life Science, Northeast Agricultural University, Harbin, China
| | - J Cang
- College of Life Science, Northeast Agricultural University, Harbin, China
| |
Collapse
|
37
|
Huang Z, Chen L, Wang Y, Fu L, Lv R. Molecular markers, pathology, and ultrasound features of invasive breast cancer. Clin Imaging 2021; 79:85-93. [PMID: 33895560 DOI: 10.1016/j.clinimag.2021.03.039] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2020] [Revised: 03/23/2021] [Accepted: 03/30/2021] [Indexed: 12/09/2022]
Abstract
INTRODUCTION Ultrasound is commonly used in breast cancer screening and diagnosis. The use of ultrasound features to predict the subtypes of invasive breast cancer is of great clinical significance, since it facilitates a fast and early diagnosis and treatment. The correlation between breast lesion ultrasound features and the breast cancer subtypes requires further investigation. METHODS 388 patients with invasive breast cancer were retrospectively analyzed by two sonographers. The tumor size, shape, margin, echogenicity, echotexture, posterior echo attenuation microcalcification, and blood vessel density were recorded. The correlation between the tumor ER, PR, HER2, and Ki67 status, the molecular subtypes, and the ultrasound features was analyzed using the chi-square test, Fisher's exact test, and multiple logistic regression. RESULTS ER and PR positivity were correlated with a low histologic grade, lymph node metastasis, and smaller-sized tumors. A hyperechoic or a mixed echogenicity was rare in the tumors of all groups but was enriched in the ER and PR tumors (9.57% and 7.64%, respectively, p < 0.01). A high percentage of posterior echo attenuation was found in the Ki67 low (53.94%) and ER+ (51.28%) tumors. Furthermore, heterogeneous and microcalcifications were enriched in HER2-positive tumors. In terms of the molecular subtypes, the luminal A subtype group had the lowest lymph node positivity and the smallest primary tumor size. The luminal B subtype had the lowest percentage of hyperechoic or mixed tumors. The HER2 subtype was positively correlated with microcalcification. Finally, TNBC showed the highest percentage of hyperechoic or mixed tumors and the lowest percentage of posterior echo attenuation and microcalcification. CONCLUSION Tumor pathologic and ultrasound features were correlated with invasive breast tumor molecular marker positivity and its molecular subtypes.
Collapse
Affiliation(s)
- Zhifang Huang
- Department of Ultrasound Medicine, Huashan Hospital Affiliated to Fudan University, China
| | - Li Chen
- Department of Ultrasound Medicine, Huashan Hospital Affiliated to Fudan University, China
| | - Yong Wang
- Department of Ultrasound Medicine, Huashan Hospital Affiliated to Fudan University, China.
| | - Lina Fu
- Department of Ultrasound Medicine, Huashan Hospital Affiliated to Fudan University, China
| | - Renhua Lv
- Department of Ultrasound Medicine, Huashan Hospital Affiliated to Fudan University, China
| |
Collapse
|
38
|
Xie W, Qian TT, Pang Y, Ye X, Huang WH, Zhu P, Fu L. [Effect of long non-coding RNA MBNL1-AS1 expression on prognosis of acute myeloid leukemia patients]. Zhonghua Yi Xue Za Zhi 2021; 101:934-938. [PMID: 33789374 DOI: 10.3760/cma.j.cn112137-20200930-02754] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To explore the prognosis effect of the expression of long-chain non-coding RNA (lncRNA) MBNL1-AS1 on acute myeloid leukemia (AML) patients. Methods: One hundred and twenty-five AML patients of the Cancer Genome Atlas (TCGA) from November 2001 to March 2010 were involved, including 70 patients who received chemotherapy only and other 55 patients treated with allogeneic hematopoietic stem cell transplantation (allo-HSCT) in addition to chemotherapy. According to the median expression of lncRNA MBNL1-AS1, patients of chemotherapy group were divided into high expression sub-group(n=35) and low expression sub-group (n=35), and patients of allo-HSCT group were also divided into high expression sub-group (n=28) and low expression sub-group (n=27) for prognosis analysis. Clinical characteristics at diagnosis, including peripheral white blood cell counts (WBC), blast percentages in peripheral blood and bone marrow (BM), French-American-British (FAB) subtypes and the frequencies of common genetic mutations in AML were described. The event-free survival (EFS) rate and overall survival (OS) rate of patients in different groups were analyzed, and the influence of the clinical characteristics of patients on the prognosis of AML was analyzed by COX multivariate analysis. Results: In the chemotherapy group, patients with low lncRNA-MBNL1-AS1 expression had significantly lower EFS and OS (60.0%, 8.6%) than patients with high lncRNA-MBNL1-AS1 expression (68.6%, 34.3%) (χ²=7.817, 10.880, all P<0.01). However, in the alloHSCT group, no significant differences were observed in EFS and OS of patients between high and low expression groups of lncRNA-MBNL1-AS1 (all P>0.05). COX multivariate analysis confirmed that age≥60 years old (EFS: HR (95%CI): 6.934 (1.918-25.075),P=0.003;OS: HR (95%CI): 4.119 (1.812-9.364), P=0.001), and low expression of lncRNA MBNL1-AS1 (EFS: HR (95%CI): 0.354 (0.126-0.941), P=0.038; OS: HR (95%CI): 0.424 (0.231-0.778), P=0.006)were independent risk factors for EFS and OS in the chemotherapy group. Conclusion: The long-chain non-coding RNA MBNL1-AS1 is related to the prognosis of AML, and its low expression is an independent poor prognostic factor in AML patients.
Collapse
Affiliation(s)
- W Xie
- Department of Hematology, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China
| | - T T Qian
- Department of Hematology, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China
| | - Y Pang
- Department of Hematology, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China
| | - X Ye
- Department of Hematology, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China
| | - W H Huang
- Department of Hematology, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China
| | - P Zhu
- Department of Hematology, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China
| | - L Fu
- Department of Hematology, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China
| |
Collapse
|
39
|
Zeng Z, Tang L, Zhou Y, Wang B, Wang Q, Zou P, Zhan X, Fu L, Li W. Effect of pidotimod on growth performance, immune function,
intestinal epithelial barriers and microbiota of piglets. J Anim Feed Sci 2021. [DOI: 10.22358/jafs/134117/2021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
40
|
Baxter NN, Sutradhar R, Dossa F, Fu L, Rochon P, Wei AC, Kennedy ED, Earle CC. Does the presence of an intact primary increase the risk of nonelective colorectal surgery in patients treated with bevacizumab? Colorectal Dis 2020; 22:1974-1983. [PMID: 32767608 DOI: 10.1111/codi.15294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/31/2020] [Accepted: 07/25/2020] [Indexed: 02/08/2023]
Abstract
AIM In patients with incurable metastatic colorectal cancer (mCRC), resection of the primary tumour is debated; however, patients with intact primaries may be at a higher risk of complications requiring surgery when receiving treatment with bevacizumab. Our aim was to estimate the risk of nonelective colorectal surgery in patients undergoing bevacizumab therapy for mCRC and evaluate the association between intact primary tumours and risk of nonelective surgery. METHOD We designed a population-based, retrospective cohort study using administrative and cancer registry data in Ontario, Canada. We included patients with mCRC who received bevacizumab from 1 January 2008 to 31 December 2014. The primary outcome was nonelective colorectal surgery after initiation of bevacizumab. We determined the cumulative incidence of nonelective colorectal surgery among patients with previously resected and unresected primaries, accounting for the competing risk of death. We explored the relationship between previous resection of the primary and need for nonelective surgery using a cause-specific hazards model, controlling for patient, tumour and treatment factors. RESULTS We identified 1840 (32.7%) patients with intact primaries and 3784 (67.3%) patients with prior resection. The cumulative incidence of nonelective surgery 1 year after initiating bevacizumab for all patients was 3.9% (95% CI 3.4-4.5%). One-year cumulative incidence was higher in those with intact primaries than in those with resected primaries (6.1% vs 2.9%, P < 0.0001). After adjustment, an intact primary remained strongly associated with nonelective colorectal surgery (hazard ratio = 2.89, 95% CI 2.32-3.61; P < 0.0001). CONCLUSION Bevacizumab is associated with a low but meaningful risk for serious gastrointestinal complications, necessitating vigilance, particularly among patients with an intact primary tumour.
Collapse
Affiliation(s)
- N N Baxter
- Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.,Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.,Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
| | - R Sutradhar
- Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.,Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.,Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
| | - F Dossa
- Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.,Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
| | - L Fu
- Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
| | - P Rochon
- Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.,Ontario Institute for Cancer Research, Toronto, Ontario, Canada
| | - A C Wei
- Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.,Memorial Sloan Kettering Cancer Center, New York City, New York, USA
| | - E D Kennedy
- Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.,Sinai Health System, Toronto, Ontario, Canada
| | - C C Earle
- Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.,Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
41
|
Wang AH, Fan WJ, Fu L, Wang XT. LncRNA PCAT-1 regulated cell proliferation, invasion, migration and apoptosis in colorectal cancer through targeting miR-149-5p. Eur Rev Med Pharmacol Sci 2020; 23:8310-8320. [PMID: 31646561 DOI: 10.26355/eurrev_201910_19142] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE Emerging studies suggested that lncRNA plays an important role in cell progression of multiple cancers. In CRC, the function of some lncRNAs has been verified to be related to cell proliferation, apoptosis, migration and invasion, providing a crucial theoretical basis for the treatment of colorectal cancer. Due to the complexity of the regulation mechanism of cell growth, the regulation mechanism related to lncRNA still needs to be further studied in CRC. PATIENTS AND METHODS The qRT-PCR assay was used to carry out the expression of prostate cancer-associated ncRNA transcripts 1 (PCAT-1) and miR-149-5p. The Western blots were used to measure the protein expression of CDK4, Cyclin D1, MMP-2, MMP-9, Bcl-2, Bax and β-actin. Additionally, flow cytometry and MTT assay were used to assess cell apoptosis and cell proliferation, respectively. Moreover, transwell assay was applied to measure the ability of cells migrated and invasion in CRC. Luciferase reporter assay was performed to detect luciferase activities. RESULTS In this study, lncRNA PCAT-1 expression was significantly upregulated in CRC cells and tissues. More than that, knockdown of lncRNA PCAT-1 inhibited cell proliferation, migration and invasion while promoted cell apoptosis in CRC cells. Of note, lncRNA PCAT-1 directly targeted miR-149-5p and miR-149-5p expression was significantly downregulated in CRC cells and tissues. Moreover, miR-149-3p reversed the suppressive effects of PCAT-1 on the cell growth of CRC cells. CONCLUSIONS Our study demonstrated that LncRNA PCAT-1 regulated cell proliferation, invasion, migration and apoptosis in colorectal cancer through targeting miR-149-5p and provided a new regulatory mechanism of CRC.
Collapse
Affiliation(s)
- A-H Wang
- Department of Biochemistry and Molecular Biology, Medical College of Yan'an University, Yan'an, Shaanxi, China.
| | | | | | | |
Collapse
|
42
|
Devarakonda A, Inoue H, Fang S, Ozsoy-Keskinbora C, Suzuki T, Kriener M, Fu L, Kaxiras E, Bell DC, Checkelsky JG. Clean 2D superconductivity in a bulk van der Waals superlattice. Science 2020; 370:231-236. [DOI: 10.1126/science.aaz6643] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2019] [Accepted: 08/21/2020] [Indexed: 11/02/2022]
Abstract
Advances in low-dimensional superconductivity are often realized through improvements in material quality. Apart from a small group of organic materials, there is a near absence of clean-limit two-dimensional (2D) superconductors, which presents an impediment to the pursuit of numerous long-standing predictions for exotic superconductivity with fragile pairing symmetries. We developed a bulk superlattice consisting of the transition metal dichalcogenide (TMD) superconductor 2H-niobium disulfide (2H-NbS2) and a commensurate block layer that yields enhanced two-dimensionality, high electronic quality, and clean-limit inorganic 2D superconductivity. The structure of this material may naturally be extended to generate a distinct family of 2D superconductors, topological insulators, and excitonic systems based on TMDs with improved material properties.
Collapse
Affiliation(s)
- A. Devarakonda
- Department of Physics, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - H. Inoue
- Department of Physics, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - S. Fang
- Department of Physics, Harvard University, Cambridge, MA 02138, USA
| | - C. Ozsoy-Keskinbora
- John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA
| | - T. Suzuki
- Department of Physics, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - M. Kriener
- RIKEN Center for Emergent Matter Science (CEMS), Wako 351-0198, Japan
| | - L. Fu
- Department of Physics, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - E. Kaxiras
- Department of Physics, Harvard University, Cambridge, MA 02138, USA
- John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA
| | - D. C. Bell
- John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA
- Center for Nanoscale Systems, Harvard University, Cambridge, MA 02138, USA
| | - J. G. Checkelsky
- Department of Physics, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| |
Collapse
|
43
|
Yin B, Ran X, Zhang C, Xie Z, Ran Y, Fu L, Pradhan S. Tinea incognito infection with Trichophyton erinacei from a pet hedgehog. Br J Dermatol 2020; 183:e92. [PMID: 32538462 DOI: 10.1111/bjd.19206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Affiliation(s)
- B Yin
- Department of Dermatovenereology, Chengdu Second People's Hospital, Chengdu, China
| | - X Ran
- Department of Dermatovenereology, West China Hospital, Sichuan University, Chengdu, China
| | - C Zhang
- State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China
| | - Z Xie
- Department of Dermatovenereology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, China
| | - Y Ran
- Department of Dermatovenereology, West China Hospital, Sichuan University, Chengdu, China
| | - L Fu
- Department of Dermatovenereology, Chengdu Second People's Hospital, Chengdu, China
| | - S Pradhan
- Department of Dermatovenereology, West China Hospital, Sichuan University, Chengdu, China
| |
Collapse
|
44
|
Mao L, Hu S, Gao Y, Wang L, Zhao W, Fu L, Cheng H, Xia L, Xie S, Ye W, Shi Z, Yang G. Biodegradable and Electroactive Regenerated Bacterial Cellulose/MXene (Ti 3 C 2 T x ) Composite Hydrogel as Wound Dressing for Accelerating Skin Wound Healing under Electrical Stimulation. Adv Healthc Mater 2020; 9:e2000872. [PMID: 32864898 DOI: 10.1002/adhm.202000872] [Citation(s) in RCA: 105] [Impact Index Per Article: 26.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2020] [Revised: 07/22/2020] [Indexed: 01/07/2023]
Abstract
Traditional wound dressings mainly participate in the passive healing processes and are rarely engaged in active wound healing by stimulating skin cell behaviors. Electrical stimulation (ES) has been known to regulate skin cell behaviors. Herein, a series of multifunctional hydrogels based on regenerated bacterial cellulose (rBC) and MXene (Ti3 C2 Tx ) are first developed that can electrically modulate cell behaviors for active skin wound healing under external ES. The composite hydrogel with 2 wt% MXene (rBC/MXene-2%) exhibits the highest electrical conductivity and the best biocompatibility. Meanwhile, the rBC/MXene-2% hydrogel presents desired mechanical properties, favorable flexibility, good biodegradability, and high water-uptake capacity. An in vivo study using a rat full-thickness defect model reveals that this rBC/MXene hydrogel exhibits a better therapeutic effect than the commercial Tegaderm film. More importantly, in vitro and in vivo data demonstrate that coupling with ES, the hydrogel can significantly enhance the proliferation activity of NIH3T3 cells and accelerate the wound healing process, as compared to non-ES controls. This study suggests that the biodegradable and electroactive rBC/MXene hydrogel is an appealing candidate as a wound dressing for skin wound healing, while also providing an effective synergistic therapeutic strategy for accelerating wound repair process through coupling ES with the hydrogel dressing.
Collapse
Affiliation(s)
- Lin Mao
- National Engineering Research Center for Nano‐Medicine Department of Biomedical Engineering College of Life Science and Technology Huazhong University of Science and Technology Wuhan 430074 China
| | - Sanming Hu
- National Engineering Research Center for Nano‐Medicine Department of Biomedical Engineering College of Life Science and Technology Huazhong University of Science and Technology Wuhan 430074 China
| | - Yihua Gao
- Center for Nanoscale Characterization & Devices Wuhan National Laboratory for Optoelectronics School of Physics Huazhong University of Science and Technology Wuhan 430074 China
| | - Li Wang
- National Engineering Research Center for Nano‐Medicine Department of Biomedical Engineering College of Life Science and Technology Huazhong University of Science and Technology Wuhan 430074 China
| | - Weiwei Zhao
- School of Mechanical and Electronic Engineering Wuhan University of Technology Wuhan 430070 China
| | - Lina Fu
- Department of Head and Neck Surgery & Communication Sciences School of Medicine Duke University Durham 27710 USA
| | - Haoyan Cheng
- School of Materials Science and Engineering Henan University of Science and Technology Luoyang 471023 China
| | - Lin Xia
- Key Laboratory of Molecular Biophysics of MOE College of Life Science and Technology Huazhong University of Science and Technology Wuhan 430074 China
| | - Shangxian Xie
- Key Laboratory of Molecular Biophysics of MOE College of Life Science and Technology Huazhong University of Science and Technology Wuhan 430074 China
| | - Weiliang Ye
- National Engineering Research Center for Nano‐Medicine Department of Biomedical Engineering College of Life Science and Technology Huazhong University of Science and Technology Wuhan 430074 China
| | - Zhijun Shi
- National Engineering Research Center for Nano‐Medicine Department of Biomedical Engineering College of Life Science and Technology Huazhong University of Science and Technology Wuhan 430074 China
| | - Guang Yang
- National Engineering Research Center for Nano‐Medicine Department of Biomedical Engineering College of Life Science and Technology Huazhong University of Science and Technology Wuhan 430074 China
| |
Collapse
|
45
|
Zhang X, Yang R, Li Z, Zhang M, Wang Q, Xu Y, Fu L, Du J, Zheng Y, Zhu J, Liu Q. Electroanalytical study of infrageneric relationship of Lagerstroemia using glassy carbon electrode recorded voltammograms. RMIQ 2020. [DOI: 10.24275/rmiq/bio1750] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
46
|
Peng J, Wen L, Fu L, Yi M. Total factor productivity of cultivated land use in China under environmental constraints: temporal and spatial variations and their influencing factors. Environ Sci Pollut Res Int 2020; 27:18443-18462. [PMID: 32193735 DOI: 10.1007/s11356-020-08264-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/12/2019] [Accepted: 02/26/2020] [Indexed: 06/10/2023]
Abstract
The continuous decline in the resource and environment-carrying capacity of cultivated land resources has seriously threatened the sustainable supply of cultivated land resources in China. Using the Hicks-Moorsteen total factor productivity index method, we examine the total factor productivity of cultivated land use (CL-TFP) in China from 2003 to 2017 under environmental constraints. We further use a panel Tobit model to estimate the effect of its influencing factors. The results show that the CL-TFP presents a fluctuating upward trend and reaches data envelopment analysis (DEA) efficiency during the sample period. The regional results reveal a significant spatial difference, especially in the mid-west region, which fails to reach DEA efficiency. China's main cultivated land did not realize economies of scale. The phenomenon of spatial polarization in what we refer to as very low-value areas and very high-value areas is clear, and the changes are gradual. Regarding the determinative influencing factors, results from the panel Tobit model show that cultivated land usage tax and environmental pollution control investment have no significant effect on CL-TFP, while income level and agricultural intermediate consumption do have a positive effect on CL-TFP. The empirical evidence can help policymakers craft and frame effective policies that improve the utilization efficiency of China's cultivated land resources.
Collapse
Affiliation(s)
- Jiachao Peng
- School of Economics and Management, China University of Geosciences, No.388 Lumo Road, Wuhan, 430074, Hubei, China
| | - Le Wen
- Energy Center, Economics Department, University of Auckland, Auckland, New Zealand
| | - Lina Fu
- International Education College, South-Central University for Nationalities, Wuhan, China
| | - Ming Yi
- School of Economics and Management, China University of Geosciences, No.388 Lumo Road, Wuhan, 430074, Hubei, China.
| |
Collapse
|
47
|
Zhang J, Wei L, Yang J, Ahmed W, Wang Y, Fu L, Ji G. Probiotic Consortia: Reshaping the Rhizospheric Microbiome and Its Role in Suppressing Root-Rot Disease of Panax notoginseng. Front Microbiol 2020; 11:701. [PMID: 32425904 PMCID: PMC7203884 DOI: 10.3389/fmicb.2020.00701] [Citation(s) in RCA: 31] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2019] [Accepted: 03/25/2020] [Indexed: 12/13/2022] Open
Abstract
Root-rot disease caused by Fusarium oxysporum is a growing problem in agriculture for commercial cultivation of Panax notoginseng. Diverse microbes colonize plant roots, and numerous earlier studies have characterized the rhizospheric microbiome of P. notoginseng; nevertheless, the function of probiotic consortia on the rhizospheric microbiome against the root-rot disease remain elusive. We have compared and described the rhizospheric microbiome of lightly and severely diseased P. notoginseng as well as the interactions of the probiotic consortia and rhizospheric microbiome, and their function to alleviate the plant diseases were explored by inoculating probiotic consortia in bulk soil. From the perspective of microbial diversity, the rhizospheric dominant bacterial and fungal genera were utterly different between lightly and severely diseased plants. Through inoculating assembled probiotic consortia to diseased plant roots, we found that the application of probiotic consortia reshaped the rhizosphere microbiome, increasing the relative abundance of bacteria and fungi, while the relative abundance of potential pathogens was decreased significantly. We developed a microcosm system that provides a preliminary ecological framework for constructing an active probiotic community to reshape soil microbiota and restrain the disease. Microbial community structure differs between lightly and seriously diseased plants. The application of probiotic consortia changes the imbalance of micro-ecology to a state of relative health, reducing plant mortality. Plant disease suppression may be achieved by seeking and applying antagonistic microbes based on their direct inhibitory capability or by restructuring the soil microbiome structure and function.
Collapse
Affiliation(s)
- Jinhao Zhang
- Key Laboratory of Agriculture Biodiversity for Plant Disease Management Under the Ministry of Education, Yunnan Agricultural University, Kunming, China
| | - Lanfang Wei
- Key Laboratory of Agriculture Biodiversity for Plant Disease Management Under the Ministry of Education, Yunnan Agricultural University, Kunming, China
| | - Jun Yang
- Key Laboratory of Agriculture Biodiversity for Plant Disease Management Under the Ministry of Education, Yunnan Agricultural University, Kunming, China
| | - Waqar Ahmed
- Key Laboratory of Agriculture Biodiversity for Plant Disease Management Under the Ministry of Education, Yunnan Agricultural University, Kunming, China
| | - Yating Wang
- Key Laboratory of Agriculture Biodiversity for Plant Disease Management Under the Ministry of Education, Yunnan Agricultural University, Kunming, China
| | - Lina Fu
- Key Laboratory of Agriculture Biodiversity for Plant Disease Management Under the Ministry of Education, Yunnan Agricultural University, Kunming, China.,Agriculture and Rural Affairs Committee of Fengdu County, Chongqing, China
| | - Guanghai Ji
- Key Laboratory of Agriculture Biodiversity for Plant Disease Management Under the Ministry of Education, Yunnan Agricultural University, Kunming, China
| |
Collapse
|
48
|
Xiong Z, Fu L, Zhou H, Liu JK, Wang AM, Huang Y, Huang X, Yi B, Wu J, Li CH, Quan J, Li M, Leng YS, Luo WJ, Hu CP, Liao WH. [Construction and evaluation of a novel diagnosis pathway for 2019-Corona Virus Disease]. Zhonghua Yi Xue Za Zhi 2020; 100:1223-1229. [PMID: 32157849 DOI: 10.3760/cma.j.cn112137-20200228-00499] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To construct and evaluate a diagnosis pathway (Xiangya pathway) for Corona Virus Disease 2019 (COVID-19). Methods: Consecutive subjects aged ≥12 years old who were screened for COVID-19 were included in Xiangya Hospital of Central South University from January 23 to February 3, 2020, and the subjects were further divided into the inception cohort and the validation cohort. The gender, age, onset time of disease of the subjects were recorded. The information of epidemiological history, fever, and the declined blood lymphocytes were collected as clinical indicators, CT scan was used to evaluate the possibility of COVID-19 and range of lung involvement. According to the current Chinese national standards, throat swabs of suspected cases were collected and the nucleic acid of COVID-19 was detected by reverse transcription-polymerase chain reaction (RT-PCR). The Xiangya pathway was constructed with multi-indexes, compared with clinical indicators, CT results and Chinese national standards, their effectiveness of detecting confirmed cases were verified in the inception and validation cohort. Results: A total of 382 consecutive adults who was screened for COVID-19 were included, and 261 cases were in the inception cohort and 121 cases were in the validation cohort. Among the 382 cases, 192 were males (50.3%) and 190 were females (49.7%), with a median age of 35 years (range: 15-92 years). There were 183 cases (47.9%) with epidemiological history, 275 cases (72.0%) with fever, 212 cases (55.5%) with decreased peripheral blood lymphocytes, 114 cases (29.8%) with positive CT findings, 43 cases (11.3%) with positive CT-COVID-19, and 30 cases (7.9%) with positive virus nucleic acid by throat swab. Compared with clinical indicators, the sensitivity and specificity of CT were 0.950 and 0.704, respectively. The accuracy of CT to make a definite diagnosis was higher than that of epidemiological history, fever, and declined blood lymphocyte count (0.809 vs 0.660, 0.532, 0.596, P=0.001, 0.002, 0.003, respectively). The sensitivity of this pathway and the pathway recommended by the Health Commission of China were both high (all were 1.000), while the specificity and accuracy of the Xiangya pathway were higher than the one recommended by the Health Commission (0.872 vs 0.765, 0.778 vs 0.592, both P<0.001). The CT-COVID-19 reduced the missed diagnosis rate caused by false negative of nucleic acid test (31 vs 64), with difference rate of 51.6%, and the positive rate of nucleic acid test was 64.5% (20/31). In validation cohort, the specificity and accuracy of the Xiangya pathway was 0.967, the positive rate of nucleic acid test was 76.9%(10/13). Conclusions: The Xiangya pathway can predict the nucleic acid test results of COVID-19, and can be applied as a reliable strategy to screen patients with suspected COVID-19 among people aged ≥12 years in areas other than Hubei during the epidemic period of COVID-19. The cohort size needs to be increased for further validation.
Collapse
Affiliation(s)
- Z Xiong
- Department of Radiology, Xiangya Hospital of Central South University, Changsha 410008, China
| | - L Fu
- Department of Infectious Diseases, Xiangya Hospital of Central South University, Changsha 410008, China
| | - H Zhou
- Department of Radiology, Xiangya Hospital of Central South University, Changsha 410008, China
| | - J K Liu
- Department of Radiology, Xiangya Hospital of Central South University, Changsha 410008, China
| | - A M Wang
- Department of Emergency, Xiangya Hospital of Central South University, Changsha 410008, China
| | - Y Huang
- Department of Infectious Diseases, Xiangya Hospital of Central South University, Changsha 410008, China
| | - X Huang
- Department of Infection Control Center, Xiangya Hospital of Central South University, Changsha 410008, China
| | - B Yi
- Department of Clinical Laboratory, Xiangya Hospital of Central South University, Changsha 410008, China
| | - J Wu
- Department of Medical Section, Xiangya Hospital of Central South University, Changsha 410008, China
| | - C H Li
- Department of Infection Control Center, Xiangya Hospital of Central South University, Changsha 410008, China
| | - J Quan
- Department of Infectious Diseases, Xiangya Hospital of Central South University, Changsha 410008, China
| | - M Li
- Department of Respiratory and Critical Care Medicine, Xiangya Hospital of Central South University, Changsha 410008, China
| | - Y S Leng
- Department of Radiology, Xiangya Hospital of Central South University, Changsha 410008, China
| | - W J Luo
- Department of Radiology, Xiangya Hospital of Central South University, Changsha 410008, China
| | - C P Hu
- Department of Respiratory and Critical Care Medicine, Xiangya Hospital of Central South University, Changsha 410008, China
| | - W H Liao
- Department of Radiology, Xiangya Hospital of Central South University, Changsha 410008, China
| |
Collapse
|
49
|
Ren HY, Fu L, Li Y. A New Coordination Polymer Based on Two Dual-Functional Ligands: Structural Insights and Treatment Effect Against Inflammatory Metrorrhagia by Inhibiting NF-κb Activation and IL-1β Release. J STRUCT CHEM+ 2020. [DOI: 10.1134/s0022476620040101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
50
|
Liu CP, Gu YY, Li SY, Chen XB, Li LG, Jiang JJ, Zhao J, Fu L, Li MS, Chen ZC. [Transbronchial lung cryobiopsy in diffuse lung disease: a pathological analysis of 173 cases]. Zhonghua Jie He He Hu Xi Za Zhi 2020; 43:228-233. [PMID: 32164094 DOI: 10.3760/cma.j.issn.1001-0939.2020.03.018] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To evaluate the value of transbronchial lung cryobiopsy (TBCB) in pathological diagnosis for diffuse lung disease. Methods: The clinicopathological data of 173 patients from the first affiliated hospital of Guangzhou medical university between Jaunary 2017 and June 2019 with transbronchial lung cryobiopsy of diffuse lung disease were retrospectively analyzed and summarized with review. Among 173 cases, TBCB and conventional transbronchial lung biopsy (TBLB) were performed in 54 patients. The size of biopsy samples and diagnostic yield were compared. Results: Among 173 cases, the diagnostic yield was 85.54% (148/173) , 160 (92.49%) cases provided definite diagnosis and valuable pathological results, according to age, sex, occupation, past history, contact history, smoking history, laboratory serology and imaging findings. Among 160 cases, there were 72 cases of known etiology (45.00%), 27 cases of idiopathic interstitial pneumonia (16.88%), 7 cases of granulomatous lesions (4.38%) and 54 cases of other types (33.75%). With TBCB and TBLB in 54 patients, the specimens sizes of TBCB and TBLB were (3.3±1.3) mm(2) and (1.0±0.3) mm(2) respectively (t'=12.67 P<0.01) . The diagnostic yields of TBCB and TBLB were 81.48% (44/54) and 42.59% (23/54) respectively (χ(2)=17.33, P<0.01) . The diagnostic yields of TBCB and TBLB for interstitial lung diseases were 48.15% (26/54) and 5.56% (3/54) respectively (χ(2)=24.94, P<0.01) . However, the diagnostic yields of TBCB and TBLB for the other diffuse lung disease except interstitial lung diseases were 33.33% (18/54) and 37.04% (20/54) respectively, with no significant difference (χ(2)=0.1624, P=0.687). Conclusion: Compared with TBLB, TBCB has obvious advantages and application value in the diagnosis of diffuse pulmonary diseases, especially interstitial pulmonary diseases.
Collapse
Affiliation(s)
- C P Liu
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Pathology Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510090, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|